# bend
BEAUTY

# Renew + Protect
Scientific Research & Evidence Summary

v.03 December, 2019

**TABLE OF CONTENTS**

# 1.0 Synopsis

*Renew + Protect*:

- Targets the root cause of aging by transforming skin from the inside out

- Provides six powerful nutrients shown in clinical trials to enhance skin health including the omega-3s EPA and DHA, the omega-6 GLA, and the strong anti-oxidants lutein, zeaxanthin and vitamin D

- Contains natural product formulation enhancers including natural mint flavour within the mini softgels and natural source grapefruit and tangerine flavours combined with monk fruit extract in the liquid version.

- Helps to increase skin hydration, firmness and elasticity, and to reduce roughness and redness (associated with skin inflammation) resulting in younger looking skin

- Helps improve symptoms such as roughness and redness, associated with skin inflammation that may result from atopic dermatitis (eczema)

- Helps reduce skin sensitivity to UV induced sunburn

- A ground breaking clinical trial measured an 84% increase in skin resistance to UV radiation induced sunburn after 8 weeks supplementation with *Renew + Protect*.

*Renew + Protect* is a mixture of high-EPA fish oil, borage oil, the anti-oxidants zeaxanthin and lutein and vitamin D designed to optimize the Skin Climate®, leading to improved skin hydration, elasticity, firmness, roughness and redness, and reduced skin sensitivity to UV induced erythema (sunburn). The product is available in packs of 120 soft gelatin capsules (mini softgels) or 200 mL of liquid in amber glass bottles supplying the following daily dose of ingredients:

| PROPER NAME(S) | SOURCE MATERIAL(S) | DOSAGE |
|---|---|---|
| Eicosapentaenoic acid (EPA) | Anchovies, sardines, mackerel and/or herring | 1050 mg |
| Docosahexaenoic acid (DHA) | Anchovies, sardines, mackerel and/or herring | 350 mg |
| Gamma-linolenic acid (GLA) | *Borago officianalis* – seed | 120 mg |
| Zeaxanthin | *Capsicum annuum L.* – fruit | 2.5 mg |
| Lutein | Tagetes erecta - flower | 5 mg |
| Vitamin D3 | Cholecalciferol from lanolin | 25 $\mu$g (1000 IU) |

*Renew + Protect* is authorized for sale by the Natural and Non-Prescription Health Product Directorate (NNHPD) of Health Canada. It has four skin related health claims. The formulation has been proven in a human intervention trial to provide significant skin photo-protection that increases with continued use in 100% of users (Morse 2017). Benefits reported in clinical studies for individual ingredients within the formulation include:

**EPA and DHA**

- Improved severity scores (Dölle 2008), scale, itch and overall subjective severity in atopic eczema (Bjorneboe 1987).

- Improved redness, scaling, inflammation, body surface area of psoriatic lesions (Mayser 1998), redness (Maurice 1987a, & 1987b), Psoriatic Association Score and itch (Lassus 1990) in psoriasis, and reduced hyperlipidemia and nephrotoxicity side effects associated with retinoid and cyclosporine therapy typically used to treat psoriasis (Allen 2001).

- Improved inflammatory and non-inflammatory acne lesions (Jung 2014).

- Increased UV- induced sunburn threshold (Pilkington 2014, Orengo 1992, Rhodes 1994, 1995 & 2003, Pilkington 2014)

**GLA**

- Improved itch, crusting, swelling and redness between 4 and 8 weeks after treatment was initiated in atopic eczema (Morse 1989 & 2006).
- Improved skin barrier function, water loss, dryness and itch in healthy elderly people (Brosche 2000) and skin moisture, water loss, elasticity, firmness, fatigue resistance, smoothness (Muggli 2005 & 2007), and scaling (De Spirt 2009) in healthy middle-aged adults.
- Reduced inflammatory lesions and sebum secretions without hormonal changes, in people with mild-to moderate facial acne (Lee 2014).

**Lutein and zeaxanthin**

- Improved skin lipid content, skin hydration, elasticity, sunburn threshold (Palombo 2007) in people with normal skin, and skin tone and luminance (brightness) in people with mild to moderately dry skin (Juturu 2016)

**Vitamin D**

- Reduced rash caused by sun exposure, when topically applied, in people who with sunlight sensitivity (Gruber-Wackernage 2011)
- Reduced Psoriasis Area Severity Index score in people with psoriasis (Perez 1996)
- mproved the SCORing Atopic Dermatitis score in people with atopic eczema (Javanbakht 2011)

All of these benefits enhance the structure and function of skin resulting in less wrinkles and more youthful appearance.

*Renew + Protect*, along with *Marine Collagen + Co-Factors*, provide the foundation for a healthy Skin Climate®.

- *Renew + Protect* provides fatty acids needed to build skin cell membranes that create an effective barrier to lock in moisture and guards against free radical damage.
- *Marine Collagen + Co-Factors* helps to build healthy collagen that forms the scaffolding upon which skin cells grow, thereby establishing a healthy skin framework. It also protects against oxidative damage which can hamper that process, through complimentary ingredients to those provided in *Renew + Protect*.

Together, these products create the necessary Skin Climate® needed to establish a starting point that is essential to maximize outcomes of a successful skin care regimen.

## 2.0 Recommended use

*Renew + Protect* (liquid and mini softgels) is authorized for sale by the NNHPD of Health Canada through the licences NPN 80056197 and NPN 80077254, respectively, in association with the following health claims.

*Claim 1:* Helps to improve symptoms such as roughness and redness, associated with atopic dermatitis (skin inflammation).

*Claim 2:* Helps to improve skin hydration, elasticity, and firmness.

*Claim 3:* Helps in reducing skin sensitivity to UV induced erythema (sunburn).

*Claim 4:* Provides antioxidants for skin health.

# 3.0 Formulation details

*Renew + Protect* is available in packs of 120 mini softgels or 200 mL of liquid in amber glass bottles. The recommended intake is one teaspoon (5 ml) of the liquid form, or 4 mini softgels daily. The medicinal ingredients, per serving, are listed in Table 1.

Table 1: Medicinal Ingredients per serving (1 tsp. (5 ml) or 4 softgels)

| PROPER NAME(S) | SOURCE MATERIAL(S) | DOSAGE |
| --- | --- | --- |
| Eicosapentaenoic acid (EPA) | Anchovies, sardines, mackerel and/or herring | 1050 mg |
| Docosahexaenoic acid (DHA) | Anchovies, sardines, mackerel and/or herring | 350 mg |
| Gamma-linolenic acid (GLA) | *Borago officianalis* – seed | 120 mg |
| Zeaxanthin | *Capsicum annuum L.* – fruit | 2.5 mg |
| Lutein | Tagetes erecta - flower | 5 mg |
| Vitamin D3 | Cholecalciferol from lanolin | 25 $\mu$g (1000 IU) |

The following non-medicinal ingredients are provided within the Liquid:

- Grapefruit and Tangerine flavours (natural source), sunflower oil, phospholipids, canola oil, tocopherols (derived from non-GMO soy), medium chain triglycerides, ascorbic acid, *Siraitia grosvenorii* (monk fruit) extract

The following non-medicinal ingredients are provided within the Mini Softgels:

- Capsule shell (bovine gelatin, glycerin, purified water), beeswax, sunflower lecithin, mint flavour (natural source), sunflower oil, safflower oil, tocopherols (derived from non-GMO soy and/or sunflower), medium chain triglycerides

The tocopherols and ascorbic acid are included as natural antioxidants to protect the fatty acid components of the products from oxidation.

The small quantities of beeswax, sunflower (oil and lecithin), phospholipids, are added as emulsifying agents to ensure that the mixture of medicinal ingredients remain evenly distributed throughout the mixture to achieve a consistent dose. The medium chain triglycerides, sunflower oil, and safflower oil are carrier oils used to standardize and deliver a specific quantity of medicinal ingredients to the formula.

## 3.1 Dosage Rationale

Numerous human intervention trials (Pilkington 2014, Rhodes 1994 & 1995, 2003, Orengo 1992) have reported significantly increased UV- induced sunburn threshold following 1800 mg – 5 g/day EPA alone (Pilkington 2014, Rhodes 2003) or with 1200 mg/day DHA (Orengo 1992, Rhodes 1994 & 1995) for as little as 4 weeks (Orengo 1992), while as little as 1800 mg of EPA daily improved symptom severity in atopic eczema (Bjorneboe 1987). *Renew + Protect*, provides slightly less (1400 mg of EPA+DHA) than the amount of omega-3 utilized in the atopic eczema trial mentioned previously. This lower dose would be expected to provide significant benefits in healthy skin in combination with the other ingredients included in *Renew + Protect*.

*Renew + Protect* provides 120 mg of GLA daily which falls within the 80-640 mg dose of GLA reported in a meta-analysis to relieve itch, crusting, swelling and redness in atopic eczema (Morse 2006). Therefore, one would expect this dose to provide significant benefits in healthy skin in combination with the other ingredients included in *Renew + Protect*.

Although EPA+DHA and GLA on their own produce significant benefits in skin, combining these nutrients would be expected to enhance outcomes. Omega-3 supplementation increases the skin EPA:arachidonic acid (AA) ratio thereby reducing pro-inflammatory prostaglandin production (Pilkington 2014) that mediates blood vessel dilation (Rhodes 1995), under basal as well as inflammatory insult conditions (Pilkington 2014). Although AA is necessary to enhance immune function during infant development (Laitinen 2006), it is believed to contribute to inflammatory symptoms. Since combining EPA and GLA can prevent an unwanted increase in AA (Barham 2000) that may occur with chronic borage oil supplementation (Surette 2003), formulations containing both of these nutrients may be more effective to treat inflammatory skin conditions than either alone (Boon 2004). This is the reason why *Renew + Protect* provides both EPA and GLA.

Clinical trials providing 6 mg of lutein combined with various other anti-oxidants (Morganti 2004) and with 0.18 mg of zeaxanthin (Morganti 2002) have reported UV-protective effects and enhanced skin moisture, respectively. Therefore, the 5 mg of lutein provided in *Renew + Protect*, that contains additional anti-oxidants, would be expected to provide similar effects. As well, 0.18 mg (Morganti 2002) and 0.6 mg (Pallombo 2007) of zeaxanthin daily have increased skin moisture and provided protection from UV-induced damage, improved elasticity and hydration, respectively. Therefore, a significantly higher dose of 2.5 mg of zeaxanthin as provided in *Renew + Protect* would be expected to provide similar benefits.

Higher vitamin D status is associated with reduced systemic inflammation (Calton 2017). Therefore, one would expect any amount of vitamin D included within a product formulation to contribute to its anti-inflammatory effects. In addition, an intervention study providing 1600 IU of vitamin D significantly decreased symptom severity in people with atopic eczema (Javanbakht 2011). Therefore, the 1000 IU of vitamin D within *Renew + Protect* would be expected to enhance the anti-inflammatory properties of the formulation.

The definitive efficacy measure of the combined ingredients within *Renew + Protect* was a clinical trial in healthy subjects where 4 capsules per day for 8 weeks significantly increased skin resistance to UV radiation induced sunburn by 84% in 100% of the subjects (Morse 2017).

## 4.0 Scientific Background

Nutritional habits play an important role in skin health, contributing to skin structure, texture, and overall appearance and also affecting the risk for skin diseases and premature skin aging (Boelsma 2003). *Renew + Protect* is a unique combination of EPA, DHA, GLA, lutein, zeaxanthin, and vitamin D (cholecalciferol) that was formulated to promote skin health. Although it was developed primarily to prevent skin aging through UV protection, its nutrient composition is also ideally suited to maintain healthy skin.

Sunburn erythema and other health risks associated with excess sun exposure including premature skin aging, immune system damage, cataracts, and non-melanoma and melanoma skin cancers (Health Effects of UV Radiation) place huge economic burdens on societies. In Canada, in 2004, the cost for melanoma treatment alone was $444 million and for non-melanoma was $88 million, and is expected to rise by 2031 to $696 million and $226 million, respectively (Canadian Partnership Against Cancer). A study including beach goers in the United States (US) found that sunburn accounts for up to 92,720 lost workdays annually, making the economic burden for work interruption plus treatment, in excess of $10 million annually (Warthan 2003).

In recent years, interest in using natural products including nutrients as photo-protectors has grown (Saewan 2015, Serafini 2015, Fernández-García 2014). Orally administered nutrients showing benefit include omega-3 fatty acids derived from fish (Pilkington 2014, Rhodes 1994, 1995 & 2003, Orengo 1992) and a variety of anti-oxidants (Fernández-García 2014) including zeaxanthin and lutein, while vitamin D exhibits anti-inflammatory effects (Krishnan 2011) in vitro (Tongkao-On 2015, Song 2013, Gordon-Thomson 2012) and in vivo (Calton 2017), and reduces sun exposure rash when topically applied to human skin (Gruber-Wackernagel 2011). In addition, oral omega-6 fatty acids, frequently sourced from borage oil, are now recognized contributors to inflammation resolution (Chiang 2017), and so may be valuable additions to products aimed at preventing/relieving inflammatory skin conditions like sunburn.

Similarly, supplementation has become an area of interest to help slow skin aging. Free radicals, reactive oxygen species (ROS) and lipid peroxides are involved in the pathogenesis and progression of accelerated skin aging when prolonged oxidative stress occurs. The use of antioxidant-related therapies in combination with fatty acids is of particular interest in combatting this assault and restoring skin homeostasis that can reduce the appearance of wrinkles, age spots and thickened skin. These nutrients can enhance wound healing (Hong 2014, Bohr 2013) as well as the structure, function and appearance of healthy skin (Muggli 2005 & 2007). They can also provide symptomatic relief of many skin disorders including atopic eczema (dermatitis) (Morse 2006), psoriasis and acne vulgaris (McCusker 2010), and may reduce side-effects associated with other skin treatments (Fabbrocini 2014, Allen 2001).

### 4.1 *Renew + Protect* to Reduce Sunburn

The efficacy and safety of *Renew + Protect* has been tested in an open label clinical trial including 20 subjects with Fitzpatrick skin phototypes I, II or III, who took four capsules daily for 8 weeks (Morse 2017). Skin on each subject's back was exposed to a progressive sequence of timed ultraviolet (UV) radiation exposure doses at baseline, and after 4 and 8 weeks treatment to determine their minimal erythema dose (MED). Results were compared before and after treatment using three paired t-tests and subsequently three linear mixed models.

1% FOR THE PLANET | MEMBER          bullfrogpowered

Treatment significantly improved tolerance to UV exposure as evidenced by increased MED at 4 and 8 weeks compared to baseline (p<0.001). This protection increased with prolonged use of *Renew + Protect* as demonstrated by progressively increased MED between baseline and 4 weeks, and again between 4 and 8 weeks (p<0.001). Nearly 86% of patients responded to treatment within 4 weeks and 100% of patients responded by the end of the study, resulting in a 39% mean increase in MED at 4 weeks, and an 84% mean increase in MED at 8 weeks compared to baseline. Treatment was well tolerated with no product associated adverse events (AE) and only a few mild and expected side effects. Results of this study showed that *Renew + Protect* safely and effectively provides significant skin photo-protection that increases with continued use.

## 4.2 Omega-3 Fatty Acids

Fatty acids, including the omega-3s, EPA and DHA, are found in dietary fat and are components of every cell membrane in the body. The types of fatty acids in the diet influence body composition, and are crucial to its function and health. They are structural components of phospholipids that comprise cell membranes and can affect their fluidity and flexibility thereby modulating the behaviour of membrane bound proteins including receptors, enzymes and ion channels that dictate cell function. They are involved in the transport and disposal of cholesterol, and are responsible for the impermeability of the skin to water and for regulation of permeability in the gut and other tissues. In addition, they are precursors for hormone-like substances that regulate a broad spectrum of functions including blood pressure control, inflammation and immunity (Griffiths 2006).

EPA and DHA are derived primarily from fish and fish oils. Although, our bodies naturally produce some EPA and DHA, the amount is too small and irregular to ensure proper biochemical functioning, with DHA synthesis being the most affected and males being particularly disadvantaged in this respect (Gerster 1998, Simopoulos 1999). In addition, limited storage of the n-3 fatty acids in adipose tissue suggests that a continued dietary supply is needed (Arterburn 2006). Currently, the dietary intake of these two nutrients is grossly inadequate according to recommendations for general populations, by dozens of government departments, international bodies, and formal and informal scientific societies and groups (Global Recommendations). The current US daily dietary intake of EPA+DHA is only 40 mg in children and teens, and 90 mg in adults (Omega-3 Fatty Acids Fact Sheet). Canadian children only eat 92.5 mg EPA + DHA daily (Madden 2009), while Canadian adults eat only 47-160 mg of DHA per day (Innis 2003, Denomme 2005, Fratesi 2009, Xie 2008). This intake data, combined with the significant efficacy of omega-3s against UV skin damage (see Section 4.2.5 Omega-3 Human Intervention Trials), leads one to speculate that nearly the entire North American population could benefit from photo-protection through omega-3 supplementation.

## 4.2.1 Omega-3 Pharmacokinetics

The pharmacokinetics of fatty acids is relatively more complex than standard drug treatments where a pure, single ingredient substance is ingested, absorbed, distributed, metabolized and excreted. Since fatty acids are structural components within the body, they can become incorporated into membranes, they are precursors for a wide variety of regulatory molecules and can be processed through beta-oxidation as a source of energy. As well, this process occurs gradually, over a long period of time following repeat ingestion. Consequently, any standard models for elucidation of their pharmacokinetics are of limited use and provide little relevant or significant information. The following is an example of the inappropriateness of such studies.

A study on the pharmacokinetics of an omega-3 oil in humans compared the relative absorption and effect on platelet function, of concentrated fish oil and tuna given to 10 subjects in a randomized crossover study. Although plasma enrichment of EPA from either preparation was similar, relative absorption of EPA from tuna was significantly greater than that from fish oil (46.6 +/- 3.0 mg/L/g EPA from tuna compared with 16 +/- 1.0 mg/L/g EPA from fish oil, P less than 0.001). Relative absorption of DHA was equivalent (54.0 +/- 9.0 mg/L/g DHA from tuna, 56 +/- 9.0 mg/L/g DHA from fish oil, NS). Platelet aggregation was significantly diminished after either preparation but bleeding time, and membrane omega-3 fatty acid content were not changed. (Silverman et al. 1991)

This design is completely inappropriate for assessment of a fatty acid supplement since it only included a single dose of product. Numerous studies in various disease states have shown that weeks of daily treatment is typically necessary before an accurate assessment can be made of the product effectiveness that corresponds to significant changes in membrane/blood fatty acid profiles (Horrobin. 1990).

In contrast to the above study, three dosages (3 g, 6 g, 12 g) of two different fish oil preparations for 28 days achieved a rapid increases in EPA and DHA plasma concentrations. There was a dose dependent increase in EPA concentrations whereas DHA plasma concentrations remained relatively constant in all dosages investigated. There was no differences in bioavailability EPA or DHA from the different types of fish oils (Marsen 1992).

A summary review of biodistribution, interconversion, and dose response data reported that EPA, but not DHA concentrations in plasma, increase in response to dietary EPA. Dietary DHA results in a dose-dependent, saturable increase in plasma DHA concentrations and modest increases in EPA concentrations. Plasma DHA concentrations equilibrate in approximately 1 month and then remain at steady state throughout supplementation. DHA doses of approximately 2 g/d result in a near maximal plasma response. Both dietary DHA and EPA reduce plasma AA concentrations. Tissue contents of DHA and EPA also increase in response to supplementation with these fatty acids (Arterburn 2006).

### 4.2.2 Omega-3 Pharmacodynamics/Mechanism of Action

The balance of omega-6 and omega-3 polyunsaturated fatty acids determine the development and severity of inflammatory responses. A high intake of omega-6 fatty acids, particularly AA, potentiates inflammatory processes while a higher omega-3 fatty acid intake has anti-inflammatory effects (Calder 2006). Therefore, correcting the omega-6 and omega-3 balance may benefit patients with skin inflammation.

The omega-3 polyunsaturated fatty acids work through a plethora of anti-inflammatory mechanisms (Calder 2009). Within skin, the long-chain polyunsaturated fatty acid (LC-PUFA) derivatives of the parent omega-3, alpha-linolenic acid (ALA), are immune modulators (McMusker 2010). These, along with omega-6 derived LC-PUFAs act through a variety of independent mechanisms as well as those involving peroxisome proliferator-activated receptors (PPARs) and Toll-like receptors (TLRs) to (McCusker 2010):

- maintain the startum corneum permeability barrier and skin appearance
- control maturation and differentiation of the stratum corneum and formation and secretion of lamellar bodies
- inhibit pro-inflammatory eicosanoids, cytokines [tumor necrosis factor-$\alpha$ (TNF-$\alpha$), interferon-$\alpha$ (IFN-$\alpha$), and interleukin (IL)-12] and lipoxygenase
- elevate the sunburn threshold
- promote tissue repair and apoptosis in malignant cells.

The outcome of these actions is clinical benefit for many skin disorders including atopic eczema (dermatitis), psoriasis, acne vulgaris, systemic lupus erythematosus, nonmelanoma skin cancer and melanoma (McCusker 2010). In addition, they reduce ultraviolet (UV) damage/photoaging (Pilkington 2014, Rhodes 2003, Orengo 1992, Rhodes 1995, Rhodes 1994), enhance wound healing (Hong 2014, Bohr 2013) and the structure, function and appearance of healthy skin (Muggli 2005, Muggli 2007), and may reduce side-effects associated with other treatments, for example erythema caused by isotretinoin (Fabbrocini 2014), and hyperlipidemia and nephrotoxicity associated with retinoid and cyclosporine therapies typically used to treat psoriasis (Allen 2001).

### 4.2.3 Omega-3 Preclinical Studies

Excess inflammation and altered inflammatory mediator metabolism is suspected to contribute to skin aging and the pathogenesis of a number of skin conditions, including UV sensitivity (Miller 1994), acne vulgaris (reviewed in (Taylor 2011), acne rosacea (Millikan 2004), eczema (Ruzicka 1986, Fogh 1989, Ikai 1993, Bieber 2008, Nicolaou 2012), hives (Sabroe 1997), and psoriasis (Brain. 1984, Grabbe 1984, Ruzicka 1986, Stone 1990, Sabroe 1997, Nicolaou 2012).

Preclinical studies in relation to atopic eczema, show that increased EPA, DHA (Park 2011) and their metabolites (Kiss 2015) within skin, reduce inflammation partly through suppressing leukotriene B4 (LTB4) production (Yoshida 2016) and the pro-inflammatory protein poly(ADP-ribose) polymerase (PARP). Resolvin E1, derived from EPA, inhibits dendritic cell migration in the skin (Sawada 2015) and suppresses eczema-like lesion development by reducing IL-4 and IFN-$\gamma$ activation of CD4(+) T cells, serum IgE levels and skin infiltration by immune cells including eosinophils, mast cells, and CD4(+) and CD8(+) T cells (Kim 2012). DHA suppresses atopic dermatitis symptoms partly through transforming growth factor-$\beta$ and IL-10 conversion of CD4 T cells to CD4 FoxP3 T regulatory cells by M2 macrophages (Haitz 2015).

Preclinical studies indicate that DHA supplementation reduces allergic sensitization to whey and allergic skin response symptoms to both whey and peanut (van den Elsen 2014). When combined with AA, it reduces the severity of allergen-induced dermatitis through a variety of mechanism (Weise 2011 & 2013).

Within keratinocytes, apoptosis is typically induced as a protective mechanism after acute exposure to UV radiation (Serini 2011). However, apoptosis resistance and carcinogenesis can follow chronic UV exposure (Serini 2011). Preclinical studies report that EPA and DHA can induce apoptosis and inhibit growth of pre-malignant keratinocytes (Nikolakopoulou 2013), inhibit cell proliferation in malignant melanoma cells (Zajdel 2013), delay the development of UVB-induced skin tumours and decrease tumour formation (Lou 2011).

EPA and DHA inhibit IL-8 production, which may partly account for their anti- inflammatory effects yielding UV-protection in skin (Storey 2005). For example, studies in keratinocytes (the most common cell type in the epidermis) and fibroblasts (which synthesize collagen) have shown that in keratinocytes, EPA and DHA reduced IL-8 secretion by 66% and 63%, respectively, and UVB-induced levels of this cytokine by 66% and 65% at 48 h, respectively. A similar pattern occurred in fibroblasts. In addition, TNF-$\alpha$-induced IL-8 secretion by keratinocytes was reduced by 54% and 42%, respectively, by EPA and DHA.

An in vivo study has shown that high-fat fish oil diet compared to a high-fat mixed-lipids diet delayed the development and decreased the formation of UVB-induced skin tumours, while simultaneously significantly decreasing UVB-induced increases in several pro-inflammatory mediators and decreasing UVB-induced programmed cell death in the epidermis (Lou 2011).

### 4.2.4 Omega-3 Human Epidemiological Studies

Epidemiological studies report that omega-3 supplementation is associated with reduced UVB-erythemal sensitivity and photo-aging (Latreille 2013). A 20 year observation study of Inuit who typically have a fish-rich diet, found low rates of melanoma and nonmelanoma skin cancer (Rhodes 2003). In a cohort of 20,785 women followed for 4.5 years, higher EPA/DHA intake was associated with an 80% lower risk of malignant melanoma (Donat-Vargas 2017). Other studies report a direct dose-response relationship between serum EPA and DHA concentration and the tumour suppressor, TP53, in the whole epidermis and basal layer (van der Pols 2011), and lower squamous cell carcinoma incidence in people with higher plasma EPA and omega-3/6 ratio (Wallingford 2013).

High dietary intake of omega-3 LC-PUFAs is associated with low acne rates, and primary signs of acne including oily skin, papules, pustules, and acne cysts are significantly lower among teenagers eating diets high in saltwater fish and seafood (Katzman 2007). Omega-3s inhibit LTB4 synthesis which reduces oil production (Katzman 2007) and inflammation through TLRs, making them likely candidates for acne treatment (McCusker 2010).

### 4.2.5 Omega-3 Human Intervention Trials

Many human intervention trials have measure the effects of omega-3 LC-PUFAs on skin.

Atopic eczema studies have included randomized, double-blind, placebo-controlled (R, DB, PC) trials where 12 weeks treatment with 5.4 g DHA daily significantly improved symptom severity scores (Dölle 2008), while 12 weeks of supplementation with 1.8 g EPA/day significantly improved scale, itch and overall subjective severity (Bjorneboe 1987).

In people with psoriasis, intravenously administered EPA+DHA improves erythema, scaling, inflammatory infiltrate, and body surface area of psoriatic lesions (Mayser 1998). Although high oral dosing is necessary to increase EPA+DHA skin content (Mayser 1998) that reduces inflammatory LTB4 (Ziboh 1986, Maurice 1987a, & 1987b), and reduces skin redness and scaling (Maurice 1987a, & 1987b), 8 weeks oral supplementation with as little as 1122 mg EPA + 756 mg DHA as ethyl ester reduced the Psoriatic Association Score, with itch responding most rapidly (Lassus 1990). Of the 80 patients treated, 7 were completely healed, 13 were >75% healed and only 14 were non-responders. Omega-3s also reduce hyperlipidemia and nephrotoxicity side effects associated with retinoid and cyclosporine therapy respectively (Allen 2001), and so are an attractive adjunct therapy for psoriasis.

Mild to moderate acne has responded to treatment with either 2000 mg/day EPA + DHA, or 400 mg/day GLA from borage or placebo in a 10 week R, PC trial, where significant improvements were achieved for inflammatory and non-inflammatory acne lesions accompanied by reduced inflammation and IL-8 (Jung 2014).

Numerous R, DB, PC (Pilkington 2014, Rhodes 2003, Orengo 1992) and open trials (Rhodes 1994 & 1995) have reported significantly increased UV- induced sunburn threshold following 1800 mg – 5 g/day EPA alone (Pilkington 2014, Rhodes 2003) or with 1200 mg/day DHA (Orengo 1992, Rhodes 1994 & 1995) for as little as 4 weeks (Orengo 1992). In addition, sunburn threshold rose progressively with increasing time throughout treatment, but fell 10 weeks after treatment cessation, indicating that routine continuous supplementation provides better protection (Rhodes 1994).

Details of these studies are summarized below:

| REFERENCE | TRIAL DESIGN | POPULATION | TREATMENT | RESULTS |
|---|---|---|---|---|
| **ATOPIC ECZEMA** | | | | |
| Bjorneboe 1987 | R, DB, PC | Subjects with **atopic eczema** | 1.8 g EPA or placebo for 12 weeks | • Compared to controls, the treatment group had improved scale (P < 0.05), itch (P <0.05), and overall subjective severity (P < 0.02). |
| Dölle 2008 | R, DB, PC | 53 subjects with **atopic eczema** (aged 18 – 40 years). | 5.4 g DHA or placebo daily at weeks 0, 4, 8, and 20 | • DHA resulted in a significant clinical improvement of eczema whereas the control treatment did not lead to significant improvements.<br>• DHA decreased SCORAD scores by week 8. |

| REFERENCE | TRIAL DESIGN | POPULATION | TREATMENT | RESULTS |
|---|---|---|---|---|
| **PSORIASIS** | | | | |
| Ziboh 1986 | Open label | 13 **psoriasis** patients | 60 – 75 g per day of fish oil (each gram contained 180 mg EPA and 120 mg DHA), for 8 weeks. | • Mild to moderate improvement in psoriatic lesions in 8 patients ($p < 0.05$) and improved clinical response correlated with high EPA/DHA ratios attained in skin tissue specimens.<br>• A possible increase in the ratio LTB5 (derived from EPA) to LTB4 [derived from AA], was responsible for inflammation reduction. |
| Maurice 1987a&b | Open label | 10 patients with severe chronic **psoriasis** that was resistant to conventional topical treatment | Fish oil containing approximately 12 g EPA daily for a minimum of 6 weeks. | • A reduction in skin redness and scaling was observed in 8 of 10 patients<br>• Substantial inhibition of inflammatory leukotriene B4 production. |
| Lassus 1990 | Open label | 80 patients with chronic, stable **psoriasis**; 34 subjects also had psoriatic arthritis | 1122 mg EPA and 756 mg DHA in ethyl ester daily for 8 weeks | • Mean Psoriatic Association scoring index (PASI) dropped to 1.98 and 1.24, four and eight weeks post treatment respectively ($P < 0.001$).<br>• Itching decreased most rapidly, followed by scaling and hardening of the plaques<br>• Skin redness was most persistent.<br>• At trial end, 7 patients were completely healed and >75% healing was observed in 13 patients. |

| REFERENCE | TRIAL DESIGN | POPULATION | TREATMENT | RESULTS |
|-----------|--------------|------------|-----------|---------|
| Mayser 1998 | R, DB, PC | 83 patients hospitalized for **chronic plaque-type psoriasis** with a severity score of at least 15 according to the Psoriasis Area and Severity Index (PASI). | Daily infusions with either an omega-3 fatty acid-based lipid emulsion (Omegavenous; 200 ml/day with 4.2 g of both EPA and DHA) or a conventional omega-6 lipid emulsion (Lipovenous; EPA+DHA < 0.1 g/100 ml) for 14 days | • Total PASI scores decreased by 11.2 and 7.5 in the omega-3 and omega-6 groups, respectively ($p$ = 0.048). <br>• Symptom severity per body area, skin redness, scaling, and overall assessment by the investigator and the patient improved more in the omega-3 group than the omega-6 group. <br>• A decrease in total PASI of ≥50% between admission and last value was seen in 37% of the omega-3 treatment group versus 23% of the omega-6 group. |
| **ACNE** | | | | |
| Jung 2014 | R, DB, PC | 45 participants with mild to moderate acne | Either 2000 mg/day EPA + DHA, or 400 mg/day GLA from borage or placebo for 10 weeks | Significant improvements were achieved for inflammatory and non-inflammatory acne lesions accompanied by reduced inflammation and IL-8 as determined by immunohistochemical staining |
| **UV PROTECTION** | | | | |
| Rhodes 1994 | Open label | 15 **healthy** subjects | 10 g fish oil daily (1800 mg EPA and 1200 mg DHA) for either 3 or 6 months | • Total omega-3 fatty acids increased significantly ($p < 0.01$). <br>• Sunburn threshold rose progressively with increasing time throughout the fish oil treatment ($p < 0.01$) but fell 10 weeks after stopping treatment ($p < 0.05$). |

| REFERENCE | TRIAL DESIGN | POPULATION | TREATMENT | RESULTS |
|-----------|--------------|------------|-----------|---------|
| Rhodes 1995. | Open label, case-control | 13 caucasian subjects with **moderate to severe sun allergy** (11 female, two male; median age 45 years) and 11 healthy volunteers | MaxEPA Fish oil (1800 mg EPA and 1200 mg DHA daily) for 3 months | • Mean sunburn threshold increased ($p < 0.01$)<br>• Forearm graded UVA challenge was positive in 10 patients at baseline, 9 of these subjects showed reduced sensitivity to blister initiation after 3 months ($p < 0.001$).<br>• Compared to control skin, the UVB- induced increase in inflammatory PGE2 production was significantly attenuated ($p < 0.05$).<br>• These results suggest that UVinduced inflammation may be partially lowered by fish oil's PGE2-lowering effects. |
| Orengo 1992 | R, DB, PC | 20 **healthy** subjects | Fish oil supplementation [2800 mg EPA and 1200 mg DHA daily} for 4 weeks | • Sunburn threshold significantly increased following supplementation ($p<0.02$). |
| Rhodes 2003 | R, DB, PC | 42 **healthy** subjects | 4 g daily of purified EPA or monounsaturated (oleic acid) placebo for 3 months | • Sunburn sensitivity was reduced with EPA supplementation; compared to baseline.<br>• UVR-induced sunburn threshold increased significantly after supplementation ($p < 0.01$). |
| Pilkington 2014 | R, DB, PC | 79 **healthy** females | 5 g EPA-rich or placebo for 12 weeks | • EPA increased RBC and dermal EPA versus control and lowering relative AA:EPA content.<br>• Pre-EPA, UVR increased various pro-inflammatory metabolites including prostaglandin (PGE)2, 12-hydroxyeicosatetraenoic acids, 12-HEPE and PGE3.<br>• Post-EPA, PGE2 was reduced in unchallenged skin while EPA-derived PGE3 and 12-HEPE were elevated post-UVR.<br>• Thus, post-EPA, PGE2 :PGE3 was lower in unchallenged and UVR exposed skin; and 12-hydroxyeicosatetraenoic acids:12-HEPE was lower in UVR-exposed skin.<br>• EPA supplemental augments skin EPA:AA content, shifting eicosanoid synthesis towards less pro-inflammatory species, and promoting a regulatory milieu under basal conditions and in response to inflammatory insult. |

### 4.3 Gamma-linolenic Acid

Gamm-linolenic acid (GLA) is an omega-6 fatty acid derived from linoleic acid (LA). Dietary GLA is relatively scarce, but it is a significant component of human milk and is abundant in evening primrose oil (EPO) and borage oil (Horrobin 1990). No LC-PUFA has been researched more thoroughly in human skin related intervention trials than GLA.

### 4.3.1 GLA Pharmacokinetics

Similar to omega-3s, elucidation of the pharmacokinetics of omega-6 fatty acids using standard techniques are of limited use. One such study reported the serum levels of 8 fatty acids over 24 hours after Epogam (a brand of EPO) supplementation in each of 6 healthy subjects. GLA showed an absorption-elimination pattern following consumption, and its AUC24h and Cmax were significantly increased over the baseline values. However, concentrations of other fatty acids did not increase, including DGLA and AA, which are metabolic products of GLA. The authors concluded that the effect of GLA supplementation on serum DGLA and AA concentrations could not be clearly established through such studies (Martens-Lobenhoffer and Meyer 1998).

### 4.3.2 GLA Pharmacodynamics/Mechanism of Action

The parent omega-6 fatty acid, LA, and its products including GLA, are structural precursors of the stratum corneum ceramides and can impact inflammation (McMusker 2010). See section 4.2.2 Omega-3 Pharmacodynamics/Mechanism of Action for further details on the mechanism of action.

GLA exhibits anti-inflammatory properties through its intermediate product, dihommogamma-linolenic acid (DGLA), where an increase in DGLA relative to AA within inflammatory cells may attenuate the biosynthesis of inflammatory AA metabolites (Kapoor 2006). This dependence on conversion of various dietary fatty acids including LA, into GLA and further metabolites to maintain homeostasis, can be particularly significant in certain segments of the population that carry underperforming alleles for some of the enzymes in the fatty acid metabolic pathway. For example, in people with atopic eczema, there is defective enzyme conversion of LA through to its metabolites, based on a study showing strong associations between blood fatty acid composition and variants in the following two human genes (Schaeffer 2006):

- FADS2 that codes for delta-6-desaturase (D6D), the enzyme that converts

    ○ LA to GLA

    ○ and is required along with various elongases to convert omega-3 LC-PUFAs between ALA to EPA as well as EPA to DHA

- FADS1 that codes for delta-5-desaturase (D5D), the enzymes that converts

    ○ DGLA to AA

    ○ and is required along with an elongase to convert to omega-3 LC-PUFAs between ALA to EPA

These abnormalities in atopics raised the possibility that supplementation with particular LC-PUFAs including GLA could bypass these defects and provide clinical benefit.

Dependence on conversion of dietary fatty acids to further metabolites is further complicated because LA and ALA are transformed to their corresponding metabolites through a shared set of enzymes that alternately desaturate and elongate the molecules. This results in competition between the omega-6s and omega-3s. For example, higher intake of EPA can block the conversion of DGLA to AA and thereby increase the concentration of DGLA and subsequently, the production of anti-inflammatory prostaglandin E1 from DGLA. As a consequence, combinations of omega-3 and omega-6 fatty acids may be more beneficial in treating inflammatory skin conditions than omega-3 or omega-6 PUFAs alone (Boon 2004). Further, combining EPA with GLA can prevent the unwanted increase in AA (Barham 2000) that may occur with chronic borage oil supplementation (Surette 2003). This lends credibility to Bend Beauty's *Renew + Protect* formulation, that provides EPA, DHA, and GLA for their combined anti- inflammatory activities.

### 4.3.3 GLA Human Epidemiological Studies

The notion that LC-PUFA deficiency might contribute to atopic eczema was first proposed by Hansen in the 1930s, who noted that EFA deficient animals had skin lesions similar to people with the condition, and atopic eczema patients being treated with a substantial quantity of LA had near normal blood LA levels, whereas their AA levels were far below normal (Hansen 1937). These results were substantiated in a case-control study in the 1980s when LA was found to be slightly above normal, but its metabolites including GLA, DGLA and AA were all significantly below normal (Manku 1984), indicating a defect in D6D activity.

### 4.3.4 GLA Human Intervention Trials

Benefits of GLA supplementation to healthy skin as well as for acne and atopic eczema treatment are well documented in human intervention trials.

To date, at least 5 meta-analyses and/or systematic reviews have evaluated the impact of GLA on atopic eczema with varying outcomes owing to study designs and selection criteria (Horrobin 2000, Morse 1989, Morse 2006, Bamford 2013, Foster 2010). Overall, these studies have shown that progressive tissue fatty acid changes accompany symptom improvements that can exceed those of conventional medications. Studies published subsequent to these meta-analyses, including similar dosages and treatment durations, showed GLA improves symptoms within 8 weeks while increasing blood levels of GLA and AA in a dose dependent manner (Chung 2013), increases plasma DGLA, and increased GLA levels correlate with symptom improvement (Simon 2014). Thus, patients without increased plasma GLA could be non-responders and their therapy ceased while those with increased GLA levels could proceed and expect to achieve successful outcomes. In addition, GLA significantly improved barrier function through reduced transepidermal water loss (TEWL), especially in those with high levels of pro-inflammatory eicosanoids and/or low levels of anti-inflammatory eicosanoids suggesting that GLA acts partly through its anti-inflammatory effects (Kawamura 2011).

The structure and function of healthy skin can be improved with GLA as indicated in a number of PC trials. Twelve weeks treatment with 345 mg/day significantly improved skin moisture, water loss, elasticity, firmness, fatigue resistance and smoothness by 13, 8, 5, 17, 14 and 22% respectively (Muggli 2005), while 475 mg/day significantly decreased water loss and improved skin moisture, smoothness and scaling (De Spirt 2009). These benefits reduce the appearance of wrinkles and provide a more youthful looking skin. Similar benefits were achieved when skin was irritated with a strong detergent prior to GLA treatment, indicating that GLA can both repair damaged skin as well as improve healthy skin (Muggli 2007). Such effects reduce inflammation, and perhaps even reduce sensitization that contributes to developing conditions such as house wife's eczema and contact dermatitis.

Acne improvement is thought to be improved by GLA through 5-alpha-reductase inhibition (Lee 2014).

A summary of the Human Intervention Trials follows:

| REFERENCE | TRIAL DESIGN | POPULATION | TREATMENT | RESULTS |
|---|---|---|---|---|
| **ATOPIC ECZEMA** | | | | |
| Morse 1989 | Meta-analysis | 300 patients ranging from 1 to 60 years of age with **atopic eczema** | 80-480 mg GLA/day from EPO with most taking 320 mg daily for 12 weeks | • Those with the greatest increases in erythrocyte membrane GLA, DGLA and AA following treatment, also had the greatest skin improvements.<br>• Improvements exceeded those achieved using their conventional long-term maintenance therapy, for overall global assessment and in particular for itch |
| Morse 2006 | Meta-analysis | 26 R, DB, PC trials spanning over two decades including 1207 patients aged 1 to 28.5 years with **atopic eczema** | Efamol® EPO providing 80-640 mg of GLA or placebo daily for 3 to 16 weeks | • GLA is a safe and effective remedy for symptomatic relief of atopic eczema with simultaneous benefits on itch, crusting, oedema and redness that become apparent between 4 and 8 weeks after treatment is initiated.<br>• The magnitude of the treatment effect is reduced in association with increasing frequency of potent steroid use. |

| REFERENCE | TRIAL DESIGN | POPULATION | TREATMENT | RESULTS |
|---|---|---|---|---|
| Foster 2010 | Meta-analysis | 11 R, DB, PC clinical studies with **atopic eczema** | 103 to 1000 mg/day of GLA from borage oil or placebo | • Studies were small or had methodological limitations<br>• Results were highly variable<br>• Most studies showed at least some benefit to patients with less severe eczema. The 4 negative outcome trials also had large placebo effects, which could have confounded the results. |
| Bamford 2013 | Meta-analysis | 1596 participants with **atopic eczema** from 19 EPO and 8 borage oil studies | EPO, borage or placebo | • No significant improvement in global eczema symptoms compared to placebo according to both doctors and patients.<br>• This analysis did not include many of the studies reported in the previous meta-analyses and that could have impacted the conclusion. |
| Stewart 1991 | Open Label | 179 patients with **moderate to severe eczema.** | 4000 to 6000 mg EPO (a source of GLA) | • 62% of patients saw improvements in at least some of the symptoms assessed (skin redness, dryness, scaling, itch, and edema) with EPO treatment.<br>• Many patients reduced or stopped taking their conventional medication, a testament to the significant improvements noted from EPO supplementation. |
| Kawamura 2011 | Open Label | 112 subjects with **dry skin and mild eczema** | GLAcontaining foods (200 mg GLA daily) for 12 weeks | • GLA had beneficial effects on skin water loss.<br>• Those with pro-inflammatory features had significant improvements, suggesting that skin barrier improvement may be associated with the generation of anti-inflammatory metabolites from GLA.<br>• There were no side effects. |
| Bahmer 1992 | R, DB, PC | 12 **atopic eczema** patients (aged 20 to 48 years) | 3000 mg (720 mg of GLA) oral borage | • 5 of 7 patients receiving borage oil had significantly improved eczema severity using the Atopic Dermatitis Area and Severity Index (ADASI) score.<br>• Only 1 of 5 in the placebo group experienced improvement while the score worsened for 3 people. |
| Landi 1993 | R, DB, PC | 24 young adults (aged 12 – 27 years) **with atopic eczema** | 4000 mg borage oil daily for 8 weeks | • Borage oil significantly improved overall severity, response, area of eczema involvement, and individual symptoms. |

1% FOR THE PLANET | MEMBER

bullfrogpowered

| REFERENCE | TRIAL DESIGN | POPULATION | TREATMENT | RESULTS |
|---|---|---|---|---|
| Melnik 1995 | R, DB, PC, single -center | 20 adults (aged 18-53 years) with **atopic eczema** | Borage oil (Glandol) and EPOcontaining product (Epoleum; as a source of GLA) for 12 weeks | • The Atopic Dermatitis and Severity Index in 9 of 10 patients in the EPO group improved. |
| Buslau 1996 | R, DB, PC | 50 adults (aged 18–61 years) with **mild to moderate eczema** | 2000 mg borage oil daily for 12 weeks. Subjects were allowed to use topical ointments and creams but no other drugs throughout the study duration. | • 78% of the borage oil group members improved with the ADASI score compared to 43% in the placebo group (p < 0.05). <br>• Borage oil significantly increased serum dihomo-$\alpha$-linolenic acid (DGLA) (p < 0.05) (a product of GLA metabolism), and substantially increased GLA and arachidonic acid (AA).- a key inflammatory intermediate. |
| **HEALTHY SKIN** | | | | |
| Brosche 2000 | Open Label | 29 **healthy** elderly people (mean age 68.6 years) | 360 or 720 mg GLA daily from borage oil (Quintesal 180, manufacturer Galderma Laboratorium GmbH, Freiburg, Germany) for 2 months. | • Borage oil produced a statistically significant improvement in skin barrier function as evidenced by a mean decrease of 10.8% in skin water loss (p<0.05). <br>• Dry skin reduced from 42% to 14% with no significant alterations in skin hydration <br>• 34% of the people noted itch at baseline, 0% noted itch after borage oil supplementation. <br>• RBC GLA, DGLA and DGLA/AA ratio increased following treatment. |
| Muggli 2005 | R, DB, PC | 40 **healthy** males and females between the ages of 32 and 56 years of age | 3000 mg daily Efamol EPO providing 345 mg GLA or placebo for 12 weeks | • Skin moisture, water loss, elasticity, firmness, fatigue resistance, and roughness significantly improved by 12.9, 7.7, 4.7, 16.7, 14.2, and 21.7%, respectively. |
| Muggli 2007 | R, DB, PC | 40 **healthy** males and females between 32 and 60 years of age that had dry and rough skin. | Experimental skin irritation was induced by a strong detergent prior to treatment with 3000 mg daily Efamol EPO providing 345 mg GLA or placebo for 12 weeks | • Skin moisture, water loss, elasticity, firmness, fatigue resistance, and roughness significantly improved by 13.9, 10.2, 3.5, 19.2, 22.2, and 13.0%, respectively. |

| REFERENCE | TRIAL DESIGN | POPULATION | TREATMENT | RESULTS |
|---|---|---|---|---|
| De Spirt 2009 | R, DB, PC | Forty-five female healthy non-smoking women, between 18 and 65 years, with sensitive and dry skin | 12 weeks of daily supplementation with either flaxseed oil providing 2.2 g of LA+ALA, borage oil providing 475 mg of GLA/day, or a placebo containing medium-chain fatty acids. | • After 6 weeks, skin water loss decreased in both treatment groups by about 10 %.<br>• After 12 weeks of flaxseed or borage oil, skin hydration significantly increased and roughness and scaling, significantly decreased compared to baseline (both $p < 0.05$). |
| **ACNE** | | | | |
| Lee 2014 | Open Label | 10 patients with **mild-to moderate facial acne vulgaris.** | Twelve weeks treatment with 320 mg/day GLA | • Significantly reduced inflammatory lesions and sebum secretions without hormonal changes |

## 4.4 Zeaxanthin and Lutein

Zeaxanthin and lutein are in the xanthophylls category of dietary carotenoids and are best known for their importance to maturing eye health and other age related conditions. However, their importance to skin care is becoming apparent. The chemical structure of lutein and zeaxanthin are very similar, differing only in the placement of one double bond. Lutein absorbs blue light and therefore appears yellow at low concentrations and orange-red at high concentrations. These yellow to red pigments are found in green leafy vegetable like spinach, and colorful fruits and vegetable like oranges and sweet corn. Lutein is one of the most common carotenoids in nature and in the human diet (Erdman 2015). Although there are currently no Recommended Daily Intakes (RDI) for lutein or zeaxanthin, they are an essential part of our diet because they cannot be made internally (Böhm 2002). The combined daily dietary intake of lutein plus zeaxanthin ranges between 2 and 26 mg, for which a lutein-to-zeaxanthin ratio of roughly 5:1 is generally assumed (Thürmann 2005).

## 4.4.1 Zeaxanthin and Lutein Pharmacokinetics

Lutein and zeaxanthin differ from other carotenoids in that they each have two hydroxyl groups, one on each side of the molecule. Zeaxanthin is a stereoisomer of lutein, differing only in the location of a double bond in one of the hydroxyl groups. The hydroxyl groups appear to control the biological function of these two xanthophylls (Johnson 2002). Dietary lutein can be converted to meso-zeaxanthin within the body. Because xanthophylls are fat-soluble nutrients, bioavailability to tissues is dependent on a number of factors, including nutrient source (whole food or supplement), state of the food (raw, cooked, or processed), extent of disruption of the cellular matrix via mastication and digestive enzymes, and absorption by the enterocytes of the intestinal mucosa (primarily the duodenum). Cooking of lutein/zeaxanthin-containing foods may increase bioavailability by disrupting the cellular matrix and the carotenoid-protein complexes (Castenmiller 1999).

After lutein and zeaxanthin are absorbed by the enterocytes they are transported across the intestinal lumen and incorporated into the chylomicrons. They reach the circulating blood and are subsequently taken up by hepatocytes, entering the hepatic circulation where they are incorporated into lipoproteins. In humans, low- and high-density lipoproteins transport lutein and zeaxanthin via the systemic circulation to various tissues (Yeum 2002)

Data on xanthophyll absorption is limited, but studies involving single dietary doses indicate lutein reaches peak concentrations in chylomicrons at approximately two hours post-ingestion (O'Neill 1998) and peaks in serum at about 16 hours post-ingestion (Kostic 1995) Lutein absorption from lutein supplements is almost twice that from vegetable sources (Castenmiller 1999) Non-dietary factors affecting absorption and bioavailability of lutein and zeaxanthin include age, body composition, gender, fat malabsorption, alcohol consumption, smoking, and liver or kidney disease (Williams 1998, Brady 1996, Alberg 2002, Albanes 1997). Carotenoids are best absorbed in the presence of fat, but as little as 3-5 g in a meal appear to ensure carotenoid absorption (van Het Hof 2002).

In a study of two volunteers treated with a 30 mg of lutein daily for 140 day, plasma concentrations plateaued after 20–40 d, with a 10-fold increase from baseline, and returned to baseline concentrations 40–50 d after supplementation was discontinued (Landrum 1997). Depletion studies estimate the terminal half-life of lutein to be roughly 76 days in healthy subjects (Burri 2001). Long-term supplementation with 4.1 and 20.5 mg lutein increased plasma lutein concentrations approximately 3.5- and 10-fold, respectively (Thürmann 2005).

### 4.4.2 Zeaxanthin and Lutein Pharmacodynamics/Mechanism of Action

Zeaxanthin and lutein are powerful antioxidants. In the skin, they help protect light-exposed tissue (Stahl 2005, Darvin 2011) and prevent oxidative tissue damage by scavenging singlet oxygen molecules and quenching free radicals (Lee 1990). This physical quenching mechanism leaves the carotenoid intact so that a regeneration mechanism is unnecessary for the carotenoid to continue functioning as an antioxidant (Sies 1995, Stahl 2002). They also prevent lipid peroxidation. Such oxidative tissue damage, along with immunosuppression and mutations caused by UV radiation, contribute to the appearance of wrinkles, dark spots and thickened skin characteristic of aging skin, and promote skin cancer development (Lee 2004).

Carotenoids, including lutein and zeaxanthin, appear to be depleted in the skin under conditions of prolonged UV light exposure (Ribaya-Mercado 1995, Sorg 2002). Skin exposure to UV rays generates reactive oxygen species, and causes inflammation in skin cells, and erythema. Intake of lutein and zeaxanthin, reduces this inflammatory response (Stahl 2002).

Zeaxanthin is not only an effective anti-oxidant in vivo, it also reduces hydroperoxide formation in dietary oils, making it an attractive ingredient to reduce oxidative degradation within fatty acid supplements (Lee 1990).

### 4.4.3 Zeaxanthin and Lutein Preclinical Studies

Zeaxanthin can prevent oxidation in lipid systems as illustrated in a study comparing the antioxidative effectiveness of four carotenoids, where all inhibit hydroperoxide formation compared to a control solution with no added carotenoids (Terao 1989).

The anti-oxidant capability of zeaxanthin has been compared to that of the highly potent synthetic anti-oxidant, Trolox. In one study, testing three different zeaxanthin isomers, two had greater free radical scavenging capacity and prevented oxidation better than Trolox, while one isomer was less effective (Böhm 2002). In a second study, zeaxanthin was reportedly more effective than Trolox (Miller 1996).

The antioxidant activity of lutein, examined by using the photochemiluminescence assay and the beta-carotene-linoleic acid model system, showed it had greater antioxidant capacity than the two other common carotenoids, beta-carotene and lycopene. (Wang 2006).

In dermal fibroblasts, melanoma cells, and ultraviolet radiation exposed fibroblasts, lutein is required to help regulate the extracellular matrix remodeling to maintain cell membrane integrity (Philips 2007).

Preclinical studies have shown that lutein supplementation causes lutein accumulation in the skin while decreasing reactive oxygen species generation following UVB exposure. In addition, tissue swelling and contact hypersensitivity typically induced by UVB exposure is significantly reduced. Authors of a study showing these effects suggested that lutein modulates the skin's response to UV radiation and may contribute to the defence against some of the deleterious effects of sunlight (Lee 2004).

### 4.4.4 Zeaxanthin and Lutein Human Epidemiological Studies

Researchers have demonstrated the presence of lutein and its oxidative metabolites in human skin (Wingerath 1998, Khachik 1995). Although a direct association between skin levels of lutein and lutein consumption has not been established, higher skin lutein levels are observed in humans who take a regular lutein-containing, multivitamin supplement (Peng 1995).

### 4.4.5 Zeaxanthin and Lutein Human Intervention Trials

Lutein and zeaxanthin studies have revealed positive effects on skin hydration, elasticity and sunburn threshold (Palombo 2007).

A summary table of the Human Intervention Trials follows:

| REFERENCE | TRIAL DESIGN | POPULATION | TREATMENT | RESULTS |
|---|---|---|---|---|
| Nakagawa 2009 | Open label | 6 **healthy** subjects | One capsule containing 9.67 mg lutein once daily for 4 weeks. | • Lutein incorporated into blood cells.<br>• Blood cell oxidative damage decreased after the ingestion<br>• Antioxidative effect was confirmed on blood cell membranes |

| REFERENCE | TRIAL DESIGN | POPULATION | TREATMENT | RESULTS |
|---|---|---|---|---|
| Morganti 2002 | R, DB, PC | 30 females (aged 48 to 59 years) with **moderate xerosis (abnormal dryness** of the skin or mucus membranes) and photo-aging (damage from prolonged exposure to UV radiation) | Oral antioxidant complex that contained 6 mg of lutein and 0.18 mg zeaxanthin daily, among other antioxidants for 8 weeks | • The amount of oxidation present in the skin significantly decreased within the first 2-weeks and continued to decrease throughout the study period.<br>• Skin moisture within 2 weeks and continued to increase throughout the study. |
| Heinrich 2003 | R, DB, PC | 24 volunteers with **skin type II** | Group 1 receiving 24 mg beta-carotene and Group 2 receiving 24 mg mixed carotenoids (8 mg each of beta-carotene, lutein, and lycopene) daily for 12 weeks. | • Group 2 patients had increased serum levels of all three nutrients<br>• Significant decrease in erythema was observed in both groups after UV exposure compared to pre-supplementation. |
| Morganti 2004 | R, DB, PC | 50 **healthy** smokers | Treatment groups applied sunscreen (SPF 20) and were given capsules twice a day, containing either 3 mg lutein, 45 mg ascorbic acid, 5 mg alpha tocopherol, and 2.5 mg alpha-lipoic acid (lutein treatment group) or capsules with 13 mg carotenoids, 2 mg lycopene, 30 mg alpha-tocopherol, 60 mg ascorbic acid, and 10 mg polyphenol (carotenoid treatment group) for 8 weeks. The control group only applied sunscreen. | • The treatment groups had significantly reduced free radicals in blood compared to control ($p<0.005$)<br>• All groups had a highly significant ($p <0.005$) increase in skin hydration compared to baseline, however the difference between groups was not significant. |
| Palombo 2007 | R, DB, PC | Forty **healthy** women (aged 25–50 years) exhibiting signs and symptoms of premature skin aging | One capsule (containing 5 mg lutein and 0.3 mg zeaxanthin) or a placebo twice daily with meals for 12 weeks | • Significant increases in skin lipids ($p < 0.05$), skin hydration, ($p < 0.05$), skin elasticity ($p < 0.05$), and sunburn threshold ($p < 0.05$) following treatment. |
| Schwartz 2016 | R, DB, PC | 31 **healthy** subjects | a supplement containing with zeaxanthin, algae extracts, peptides, and hyaluronatein for 12 weeks | • Improved hydration within 2 weeks and total wrinkle count by 4 weeks<br>• Statistically significant differences from baseline scores for average wrinkles severity at week 12 visit in the active group compared to placebo |

| REFERENCE | TRIAL DESIGN | POPULATION | TREATMENT | RESULTS |
|-----------|--------------|------------|-----------|---------|
| Juturu 2016 | R, DB, PC | 46 **healthy** subjects aged 18-45 years with mild-to-moderate dry skin | 10 mg lutein and 2 mg zeaxanthin isomers or a placebo daily for 12 weeks. | • Overall skin tone (P<0.0237) and luminance values were significantly improved in the active group compared to placebo<br><br>• Mean minimal erythemal dose and individual typological angle, which signifies lighter skin tone, was increased with active.<br><br>• Overall, showed that lutein and zeaxanthin improved skin tone, luminance (brightness) and sunburn sensitivity. |

## 4.5 Vitamin D

Vitamin D is a fat soluble vitamin found in some foods including fish and eggs, and can also be manufactured in skin upon exposure to UVB rays from sunlight. Vitamin D is required to absorb calcium and promote bone growth, but its requirement for skin health is becoming increasingly obvious. There is evidence of widespread sub-clinical vitamin D deficiency (Hyppönen 2007) that is aggravated by long hours of work indoors and avoidance of sunshine aimed at reducing skin cancer risk (Hyppönen 2010).

Vitamin D exists in several different forms including D1 - D5 that differ primarily in their side chains. The two major forms are vitamin D2 or ergocalciferol, and vitamin D3 or cholecalciferol. These are known collectively as calciferol. The majority of circulating vitamin D, known as serum 25-hydroxyvitamin D [25(OH)D] and that is necessary to maintain health and function of the immune, reproductive, muscular, skeletal and integumentary system, originates from vitamin D3 (cholecalciferol) and reflects endogenous synthesis from exposure to sunlight as well as intake from the diet (Calvo 2005).

There are very few dietary sources of vitamin D. Oily fish such as herring, mackerel, pilchards, sardines and tuna are rich sources but their consumption in some countries is low. The only other useful sources are eggs, fortified margarines (required in some countries by law to contain vitamin D) and some fortified yoghurts and breakfast cereals. However, a recent global review of vitamin D status has shown that its intake is often too low to sustain healthy circulating 25(OH)D in countries without mandatory staple food fortification and is even too low in countries that do fortify due to low milk consumption, vegetarianism, non-supplement use and low fish intake (Calvo 2005). Supplement use contributed 6-47% of the average vitamin D intake in some countries. In 2005, the average dietary intake of vitamin D was in the range of 3 ug = 120 IU per day in most countries and did not exceed 9 ug = 361 IU per day in any of the countries surveyed including the United States, Canada, the United Kingdom, Ireland, Scotland, Australia, Europe, Japan and various other countries. The recommended daily intake of vitamin D for adults 19–70 years old is 600 IU and for those aged 71 years and older it is 800 IU (NIH)

Vitamin D deficiency is defined as serum 25(OH)D of less than 25-50 nmol/L. Approximately one billion people worldwide are estimated to be vitamin D deficient with people living in Europe, the Middle East, China and Japan at particular risk (Vieth 2007, Lips 2007). Deficiency is more common in women than men (9.2% verses 6.6%) (Hyppönen 2010).

US public health authorities recommend that men, women and children reduce sunlight exposure to prevent skin cancer. However, increasing numbers of Americans suffer from vitamin D deficiencies and serious health problems caused by insufficient sun exposure necessary for endogenous vitamin D synthesis. In addition, sunscreens reduce vitamin D production, prompting recommendations to warn about vitamin D deficiency associated with their use (Hoel 2016). For these reasons alone, vitamin D is considered an important nutrient for inclusion in dietary supplements aimed at photo-protection. However, vitamin D also regulates numerous functions within the skin (Bikle 2012), exhibits anti-inflammatory effects (Krishnan 2011) in vitro (Tongkao-On 2015, Song 2013, Gordon-Thomson 2012) and in vivo (Calton 2017), and reduces polymorphic light eruption when topically applied to human skin (Gruber-Wackernage 2011).

### 4.5.1 Vitamin D Pharmacokinetics

Vitamin D within the body is derived from two sources:

- D3 (cholecalciferol), the more bioactive form is produced in the skin on exposure to UVB radiation, and is also present is some animal foods (e.g. fish and liver) and supplements.

- D2 (ergocalciferol) is found in vegetable food sources.

For most people, the major supply is from the action of sunlight on skin with food sources contributing only a small amount. Solar ultraviolet-B radiation (UVB; wavelengths of 290 to 315 nanometers) stimulates the production of vitamin D3 from 7-dehydrocholesterol (7-DHC) in the epidermis of the skin. The efficiency of vitamin D3 synthesis depends on the number of UVB photons that penetrate the epidermis. During the winter months in some countries however, there is no UVB radiation of the appropriate wavelength needed for vitamin D production. Thus, winter levels are dependent on the amount of vitamin D formed during the previous summer and there is a marked seasonal variation in plasma levels. Vitamin D status is also very much dependent on the time spent out of doors during the day, which itself depends on mobility, institutionalisation, weather and cultural influences upon skin exposure (COMA 1991).

The vitamin D from food or supplements is absorbed in the part of the small intestine immediately downstream from the stomach. Stomach juices, pancreatic secretions, bile from the liver and the integrity of the wall of the intestine all have some influence on how much of it is absorbed. Since vitamin D is a fat soluble vitamin, its absorption can be maximized by consuming sufficient healthy fats. In addition, maintaining healthy gut flora enhances absorption within the small intestine, provided sufficient quantities of bile salts are also available (Vitamin D Council).

Vitamin D3 is a lipophilic molecule similar to cholesterol and so requires a protein carrier for solubility in plasma. When absorbed from the gut, vitamin D enters the circulation on chylomicrons first, and it is only slowly transferred to vitamin D binding protein (DBP). Vitamin D3 made during skin synthesis is bound rapidly to DBP and so is introduced into metabolism quicker than diet derived vitamin D. Peripheral tissues, such as adipose tissue and muscle, uptake vitamin D via the action of lipoprotein lipase. The liver absorbs what is left in the chylomicron remnant and quickly removes it from the bloodstream. Vitamin D has a short plasma half-life of 4 – 6 h while the whole-body half-life is 2 months (Jone 2008).

Vitamin D is metabolized first to 25OHD, then to the hormonal form 1,25-dihydroxyvitamin D (1,25(OH)2D). The three main steps in vitamin D metabolism, 25-hydroxylation, 1$\alpha$-hydroxylation, and 24-hydroxylation are all performed by cytochrome P450 mixed-function oxidases (CYPs). These enzymes are located either in the endoplasmic reticulum (e.g., CYP2R1) or in the mitochondria (e.g., CYP27A1, CYP27B1, and CYP24A1). 1,25(OH)2D is the ligand for the vitamin D receptor (VDR), a transcription factor, binding to sites in the DNA called vitamin D response elements (VDREs). There are thousands of these binding sites regulating hundreds of genes in a cell-specific fashion in nearly every tissue within the body, including skin (Bikle 2014).

### 4.5.2 Vitamin D Pharmacodynamics/Mechanism of Action

The keratinocytes of the skin are unique because they possess both the enzymatic machinery to product vitamin D, to metabolize it to active metabolites, in particular 1,25(OH)(2)D, and the VDR that enables the keratinocytes to respond to the 1,25(OH)(2)D thus generated. Numerous functions of the skin are regulated by vitamin D and/or its receptor. These include inhibition of proliferation, stimulation of differentiation including formation of the permeability barrier, promotion of innate immunity, regulation of the hair follicle cycle, and suppression of tumor formation (Bikle 2012).

### 4.5.3 Vitamin D Preclinical Studies

In vitro studies have shown that vitamin D reduces UV-induced damage, including inflammation, sunburn, and photo-associated immunosuppression, and carcinogenesis (Tongkao-On 2015, Song 2013, Gordon-Thomson 2012).

Nonmelanoma skin cancer is a condition of increased proliferation and decreased differentiation of keratinocytes (Bikle 2014). Lack of the VDR in keratinocytes predispose the host to UVB and chemically induced skin cancer (Teichert et al., 2011), and topical application of 1,25(OH)2D appears to be photoprotective (Mason and Reich-rath, 2013).

### 4.5.4 Vitamin D Human Epidemiological Studies

A human epidemiology study has associated higher vitamin D status with reduced systemic inflammation (Calton 2017). The aim of the study was to track seasonal variations in 25(OH)D and investigate the influence on whole body energy metabolism, circulating peripheral blood mononuclear cell (PBMC) bioenergetic profiles, and markers of systemic inflammation. The study included 30 adult Australians of European origin, aged between 20 and 70 years who supplied blood samples for testing in the summer and winter. 25(OH)D increased from winter to summer and was accompanied by significant improvements in indices of insulin sensitivity and mitochondrial function. Markers of systemic inflammation including MCP-1, IL-6, IL-8, IL-10, and IL-12p70 decreased significantly in summer compared to winter. Participants who entered winter with a low 25(OH)D (<50 nmol/L), had the greatest alteration in bioenergetic parameters in summer, relative to those with winter 25(OH)D concentrations of 50–75 nmol/L or >75 nmol/L.

### 4.5.5 Vitamin D Human Intervention Trials

Topically applied vitamin D has been shown to reduce skin rash caused by sunlight exposure (Gruber-Wackernage 2011) while oral supplementation trials have reported improvements in psoriasis (Perez 1996) and atopic eczema (Javanbakht 2011) symptoms.

A summary of the Human Intervention Trials follows:

| REFERENCE | TRIAL DESIGN | POPULATION | TREATMENT | RESULTS |
|---|---|---|---|---|
| Gruber-Wackernage 2011 | R, DB, PC | 13 patients with **polymorphic light eruption** | Subjects pretreated their skin on two symmetrically located test fields with calcipotriol or placebo cream twice daily for 7 days before the start of photoprovocation testing with solar-simulated UV radiation. | • Compared with placebo calcipotrial pretreatment significantly reduced symptoms on average by 32% throughout the observation period starting at 48 h until 144 h after the first photoprovocation exposure.<br>• Calcipotriol diminished the polymorphic light eruption test score in all 12 photoprovocable patients (P = 0·0005). |
| Perez 1996 | R, DB, PC | 85 **psoriasis** patients | Oral calcitriol (1,25-dihydroxyvitamin D3) or placebo for 24 months | • 88.0% had some improvement in their disease while 26.5, 36.2, and 25.3%, experienced complete, moderate and slight improvement.<br>• The mean Psoriasis Area Severity Index score (PASI) decreased from 18.4 at baseline to 9.7 and 7.8 after 6 and 24 months of calcitriol treatment, respectively. |
| Javanbakht 2011 | R, DB, PC | 45 subjects with **atopic eczema** | Four groups treated for 60 days with placebo or group D [1600 IU vitamin D(3)]; group E (600 IU synthetic all-racalpha-tocopherol); and group DE [1600 IU vitamin D(3) plus 600 IU synthetic all-rac-alpha-tocopherol]. | • SCORAD was reduced after 60 days in groups D, E and DE by 34.8%, 35.7% and 64.3%, respectively (p = 0.004).<br>• Objective SCORAD also showed significant improvement. There was a positive correlation between SCORAD and intensity (objective, subjective, and extent) (p < 0.001). |

## 4.6 Human Intervention Trials including Combinations of Ingredients within *Renew + Protect*

A number of studies providing mixtures of various ingredients within *Renew + Protect* have reported enhanced skin elasticity and barrier function in people with healthy skin (Segger 2008), and improved hydration (Fabbrocini 2014) and reduced inflammation (Jung 2014) and skin lesions in acne patients (Rubin 2008).

A summary of the Human Intervention Trials follows:

| REFERENCE | TRIAL DESIGN | POPULATION | TREATMENT | RESULTS |
|---|---|---|---|---|
| Rubin 2008 | Open label | 5 subjects with **mild to moderate acne** | 4 capsules per day of the supplement Perfect Skin, Genuine Health Inc, Toronto, Canada, that contains 250 mg EPA, 3.75 mg zinc gluconate, 50 mcg selenium, 50 mcg chromium, and 50 mg epigallocatechin gallate per capsule for at least 2 months. | • 4 subjects had a reduced total lesion count, with a range of 11 to 41 less lesions after 2 months.<br><br>• The average total lesion count among the group dropped from 62.8 to 40.4 with the most significant difference noted in the area of inflammatory lesions.<br><br>• No subject experienced a worsening of inflammatory acne lesions during the 2 months and all had at least some reduction in inflammatory papules (small rounded bumps rising from the skin), with the average inflammatory lesion count dropping from 20.8 at baseline to 6.8 after 2 months. |
| Segger 2008 | R, DB, PC | 24 **healthy** women (aged 40 to 60 years) | An oil formulation containing 1168 mg EPA, 745 mg DHA, and 193 mg GLA for 3 months | • Skin elasticity increased by 10 compared to the control group (P = 0.0298).<br><br>• There was also a trend towards a positive influence on the skin's barrier function. |
| Jung 2014 | R, DB, PC | 45 participants with **mild to moderate acne** | 2000 mg/day EPA + DHA, or 400 mg/day GLA from borage or placebo | • Significant improvements in both treatment groups for inflammatory and non-inflammatory acne lesions accompanied by reduced inflammation and IL-8 .<br><br>• Patient subjective assessment of improvement showed a similar result.<br><br>• Heamatoxylin & eosin staining of acne lesions showed reductions in inflammation and immunohistochemical staining intensity for interleukin-8.<br><br>• No severe adverse effect was reported. |

| REFERENCE | TRIAL DESIGN | POPULATION | TREATMENT | RESULTS |
|-----------|--------------|------------|-----------|---------|
| Fabbrocini 2014 | R, DB, PC | 48 patients with **nodular acne** (32 females and 16 males) | Either isotretinoin therapy (20-30 mg/day) + a dietary supplement containing GLA, LA vitamin E, vitamin C, beta-carotene, coenzyme Q10 and Vitis vitifera twice daily, or only isotretinoin (20-30 mg/day) for 6 months. | • Patients treated with dietary supplement had lower side effects, with a less degree of erythema and dryness, and greater degree of hydration.<br>• A greater adherence to therapy was also reported. |

## 5.0 Safety

### 5.1 Fatty Acids

The Health Canada NNHPD, has authorized sale of up to 5 g of EPA+DHA daily in adults with lower amounts based on body weight in children, without need for cautions, warning, contraindication or known adverse reactions displayed on product labels (Fish Oil Product Monograph). A similar use has been authorized for up to 1.35 g/day of GLA from borage oil in adult populations (Borage Oil Product Monograph). *Renew + Protect* provides substantially less than either of these amounts and so would not be expected to produce any known adverse reactions attributable to its fatty acid content.

Although increasing dietary LC- PUFA intake is beneficial to skin health, the same dietary changes may adversely affect some indices of lipid peroxidation. Therefore, adequate intake of antioxidants is necessary during LC- PUFA supplementation to prevent harmful oxidative stress (Jenkinson 1999). Inclusion of zeaxanthin and lutein in *Renew + Protect* ensures powerful anti-oxidant capacity.

### 5.2 Zeaxanthin and Lutein

No toxicities or adverse reactions have been reported in the scientific literature for lutein/zeaxanthin at doses of up to 40 mg daily for two months (Dagnelie 2000, Hendler 2008). Fijians consume an average of 25 mg lutein daily throughout their lifetime without any toxic effects (Le Marchand 1995). Ames testing has demonstrated an absence of any mutagenic effect for purified lutein (Gonzalez 1997). Lutein was not only found to be non-mutagenic at 334, 668 and 1335 $\mu$g/plate doses, but it showed an anti-mutagenic effect in a dose-dependent manner. Similar results were found in a chromosome aberration test using Chinese hamster ovary cells for the evaluation of clastogenicity and anti-clastogenicity of lutein at 66.8, 133.5 and 267.0 mg/L (Wang 2006).

Health Canada's NNHPD has issued a monograph for lutein and zeaxanthin that includes safety information (Marigold Monograph). Neither the U.S. Food and Drug Administration nor the European Food Safety Authority consider lutein an essential nutrient or have acted to set a tolerable upper intake level for either lutein or zeaxanthin (Carotenoids). However, the observed safe level (OSL) for lutein, based on a non-government organization evaluation, is 20 mg/day (Shao Shao2006). An acceptable daily intake level for zeaxanthin has been proposed as 0.75 mg/kg of body weight/day, which equals 53 mg/day for a 70 kg adult (Edwards 2016). In humans, an intake of 20 mg of zeaxanthin per day for up to six months had no adverse effects (Edwards 2016). Based on these observations, there is no concern that the quantities of either lutein or zeaxanthin provided in a daily dose of *Renew + Protect* would produce any toxic effects.

### 5.3 Vitamin D

There has been little toxicity reported in adults taking doses of Vitamin D as high as 10,000 IU/d (250 $\mu$g/d) (Hathcock 2007, Heaney 2008, Vieth 1999), although toxicity becomes generally present at 20,000 IU/d (500 $\mu$g/d). Recently, a randomized, controlled trial, including 350 women with a singleton pregnancy at 12 to 16 weeks' gestation (i.e. a high risk group compared to a non-pregnant, normal population) were supplemented with 400 (10$\mu$g), 2000 (50$\mu$g), or 4000 IU(100 $\mu$g) of vitamin D per day until delivery. There were no differences between groups on any safety measure. Not a single adverse event was attributed to vitamin D supplementation or circulating 25(OH)D levels (Hollis 2011). *Renew + Protect* provides 1000 IU (25 $\mu$g) per day of vitamin D, which is 4 times less than the maximum dose provided in this study of high risk subjects. Therefore, it is unlikely that the quantity of vitamin D provided in *Renew + Protect* would produce any toxic effects.

### 5.4 Risk Information

Health Canada's NNHPD has reviewed efficacy and safety information similar to the above, in consideration of the intended use of Bend Beauty's *Renew + Protect*. Based on their assessment of the evidence, they require the following risk information to be displayed on the product label.

### 5.4.1 Caution(s) and Warning(s)

None

### 5.4.2 Contraindication(s)

None

### 5.4.3 Known adverse reaction(s)

None

## 6.0 References

Albanes D, Virtamo J, Taylor PR, et al. Effects of supplemental beta-carotene, cigarette smoking, and alcohol consumption on serum carotenoids in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Am J Clin Nutr 1997;66:336-372.

Alberg A. The influence of cigarette smoking on circulating concentrations of antioxidant micronutrients. Toxicology 2002;180:121-137.

Allen BR. Fish oil in combination with other therapies in the treatment of psoriasis. World Rev Nutr Diet 2001;66:436-45.

Arterburn LM, Hall EB, Oken H. Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am J Clin Nutr. 2006 Jun;83(6 Suppl):1467S-1476S.

Bahmer FA, Schafer J. [Treatment of atopic dermatitis with borage seed oil (Glandol) a time series analytic study]. Kinderarztl Prax 1992;60(7):199-202.

Bamford JT, Ray S et al. Oral evening primrose oil and borage oil for eczema. Cochrane Database Syst Rev. 2013 Apr 30;(4):CD004416. doi: 10.1002/14651858. CD004416.pub2.

Barham J B, Edens MB et al. Addition of eicosapentaenoic acid to gamma-linolenic acidsupplemented diets prevents serum arachidonic acid accumulation in humans. J Nutr 2000;130(8): 1925-1931.

Bieber T. Atopic dermatitis. N Engl J Med 2008;358(14):1483- 1494.

Bikle DD. Vitamin D and the skin: Physiology and pathophysiology. Rev Endocr Metab Disord. 2012 Mar;13(1):3-19. doi: 10.1007/s11154-011-9194-0.

Bikle DD. Vitamin D Metabolism, Mechanism of Action, and Clinical Applications. Chem Biol. 2014 Mar 20; 21(3): 319–329.

Bjorneboe A, Soyland E et al. Effect of dietary supplementation with eicosapen-taenoic acid in the treatment of atopic dermatitis. Br J Dermatol 1987;117(4): 463469.

Boelsma E, van de Vijver LP et al. Human skin condition and its associations with nutrient concentrations in serum and diet. Am J Clin Nutr 2003;77(2): 348-355.

Bohr S, Patel SJ et al. Resolvin D2 prevents secondary thrombosis and necrosis in a mouse burn wound model. Wound Repair Regen. 2013 Jan-Feb;21(1):35-43. doi: 10.1111/j.1524-475X.2012.00853.x.

Böhm V, Puspitasari-Nienaber NL, Ferruzzi MG, Schwartz SJ. Trolox equivalent anti-oxidant capacity of different geometrical isomers of alpha-carotene, beta-carotene, lycopene, and zeaxanthin. J Agric Food Chem 2002:50:221-6.

Boon H. and Smith M. The Complete Natural Medicine Guide to the 50 Most Common Medicinal Herbs. Toronto, Robert Rose Inc. 2004.

Brady WE, Mares-Perlman JA, Bowen P, Stacewicz-Sapuntzakis M. Human serum carotenoid concentrations are related to physiologic and lifestyle factors. J Nutr 1996;126:129-137.

Brain S, Camp R et al. The release of leukotriene B4-like material in biologically active amounts from the lesional skin of patients with psoriasis. J Invest Dermatol 1984;83(1): 70-73.

Brosche T, Platt D. Effect of borage oil consumption on fatty acid metabolism, transepidermal water loss and skin parameters in elderly people. Arch Gerontol Geriat 2000;30(2):139150.

Burri BJ, Neidlinger TR, Clifford AJ. Serum carotenoid depletion follows first-order kinetics in healthy adult women fed naturally low carotenoid diets. J Nutr 2001;131:2096–100

Buslau M, Thaci D. Atopische dermatitis: Borretschol zur systemischen therapie [Atopic dermatitis: Borage oil for systemic therapy]. (German). Zeitschrift Dermatol 1996;182(3) 131–136.

Calder PC. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. AmJ Clin Nutr 2006;83(6 Suppl):1505S-1519S.

Calder PC. Polyunsaturated fatty acids and inflammatory processes: New twists in an old tale. Biochimie 2009;91(6):791-795.

Calton EK, Keane KN, Raizel R, Rowlands J, Soares MJ, Newsholme P. Winter to summer change in vitamin D status reduces systemic inflammation and bioenergetic activity of human peripheral blood mononuclear cells. Redox Biol. 2017:12:814-820.

Calvo MS, Whiting SJ, Barton CN. Vitamin D intake: A global perspective of current status. J Nutr 2005;135:310-316.

Carotenoids. Micronutrient Information Center, Linus Pauling Institute, Oregon State University, Corvallis. July 2016. http://lpi.oregonstate.edu/mic/dietary-fac-tors/phytochemicals/carotenoids (accessed on November 12, 2017).

Castenmiller JJ, West CE, Linssen JP, et al. The food matrix of spinach is a limiting factor in determining the bioavailability of beta-carotene and to a lesser extent of lutein in humans. J Nutr 1999;129:349-355.

Chiang N, Serhan CN. Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors. Mol Aspects Med. 2017 Dec;58:114-129.

Chung BY, Kim JH et al. Dose-dependent effects of evening primrose oil in children and adolescents with atopic dermatitis. Ann Dermatol 2013;25(3);285-291.

COMA. Dietary Reference Values for food energy and nutrients for the United Kingdom. 1991. HMSO.

Dagnelie G, Zorge IS, McDonald TM. Lutein improves visual function in some patients with retinal degeneration: a pilot study via the Internet. Optometry 2000;71:147-164.

Darvin ME, Sterry W, Lademann J, Vergou T. The role of carotenoids in human skin. Molecules 2011:16:10491-10506.

Denomme J, Stark K, Holub B, Directly quantitated dietary n-3 fatty acid intakes of pregnant Canadian women are lower than current dietary recommendations, J. Nutr. 2005:135:206–211.

De Spirt S, Stahl W et al. Intervention with flaxseed and borage oil supplements modulates skin condition in women. Br J Nutr 2009;101(3):440-445.

Dölle C, Metzger S et al. Docosahaexaenoic acid (DHA) supplementation in atopic eczema: a randomized, doubleblind, controlled trial. Br J Dermatol 2008;158: 808-817.

Donat-Vargas C, Berglund M et al. Dietary polychlorinated biphenyls, long-chain n-3 polyunsaturated fatty acids and incidence of malignant melanoma. Eur J Cancer. 2017 Feb;72:137-143. doi: 10.1016/j.ejca.2016.11.016.

Edwards JA.Zeaxanthin: Review of Toxicological Data and Acceptable Daily Intake. Journal of Ophthalmology. 2016: 3690140. PMC 4738691 Freely accessible. PMID 26885380. doi:10.1155/2016/3690140 https://www.hindawi.com/journals/joph/2016/3690140/

Erdman JW Jr, Smith JW, Kuchan MJ, Mohn ES, Johnson EJ, Rubakhin SS, Wang L, Sweedler JV, Neuringer M. Lutein and Brain Function. Foods. 2015 Dec;4(4):547-564. Epub 2015 Oct 9.

Fabbrocini G, Cameli N et al. A dietary supplement to reduce side effects of oral isotretinoin therapy in acne patients. G Ital Dermatol Venereol. 2014 Aug;149(4):441-5.

Fernández-García E. Skin protection against UV light by dietary anti-oxidants. Food Funct. 2014:5:1994-2003.

Fogh K, T Herlin et al. Eicosanoids in skin of patients with atopic dermatitis: prostaglandin E2 and leukotriene B4 are present in biologically active concentrations. J Allergy Clin Immunol 1989;83 (2 Pt 1):450-455.

Foster R H, Hardy G et al. Borage oil in the treatment of atopic dermatitis. Nutrition 2010;26(7-8):708-718.

Fratesi JA, Hogg RC, Young-Newton GS, Patterson AC, Charkhzarin P, Block Thomas K et al. Direct quantitation of omega-3 fatty acid intake of Canadian residents of a long-term care facility. Appl. Physiol. Nutr. 2009:34:1–9.

Gerster H. Can adults adequately convert alpha-linolenic acid (18:3n-3) to eicosapentaenoic acid (20:5n-3) and docosahexaenoic acid (22:6n-3). Int J Vitam-Nutr-Res 1998;68(3):159-73.

Gonzalez de Mejia E, Ramos-Gomez M, LoarcaPina G. Antimutagenic activity of natural xanthophylls against aflatoxin B1 in Salmonella typhimurium. Environ Mol Mutagen 1997;30:346-353.

Gordon-Thomson C, Gupta R, Tongkao-on W, Ryan A, Halliday GM, Mason RS. 1$\alpha$,25 dihydroxyvitamin D3 enhances cellular defences against UV-induced oxidative and other forms of DNA damage in skin. Photochem Photobiol Sci 2012:11:1837-1847.

Grabbe J, Czarnetzki BM et al. Identification of chemotactic lipoxygenase products of arachidonate metabolism in psoriatic skin. J Invest Dermatol 1984;82(5): 477-479.

Griffiths G, Morse N. Clinical applications of C18 and C20 chain length poly-unsaturated fatty acids and their biotechnological production plants. JOACS 2006;83(3):171-185.

Gruber-Wackernage A, Bambach I, Legat FJ, Hofer A, Byrne SN, Quehenberger F, Wolf P. Randomized double-blinded placebo-controlled intra-individual trial on topical treatment with a 1,25-dihydroxyvitamin D$_3$ analogue in polymorphic light eruption. Br J Dermatol. 2011:165:152-63.

Haitz KA, Anandasabapathy N. Docosahexaenoic Acid alleviates atopic dermatitis in mice by generating T regulatory cells and m2 macrophages. J Invest Dermatol. 2015 Jun;135(6):1472-4. doi: 10.1038/jid.2014.536.

Hansen. Serum lipids in eczema and other pathological conditions. American Journal of Diseases of Children. 1937:53:933-946.

Hathcock J N, Shao A, Vieth R, Heaney R. Risk assessment for vitamin D. Am J Clin Nutr 2007;85(1):6-18.

Heaney RP. Vitamin D: criteria for safety and efficacy. Nutrition Reviews 2008;66(10Suppl 2):S178-S181.

Heinrich U, Gartner C, Wiebusch M, et al. Supplementation with beta-carotene or a similar amount of mixed carotenoids protects humans from UV-induced erythema. J Nutr 2003;133:98-101.

Hendler SS, Rorvik DM, eds. PDR for Nutritional Supplements. 2nd ed. Thomson Reuters; 2008.

Hoel DG, Berwick M, de Gruijl FR, Holick MF. The risks and benefits of sun exposure. Dermatoendocrinol 2016:0:1-17.

Hollis BW, Johnson D, Hulsey TC, Ebeling M, Wagner CL. Vitamin D supplementation during pregnancy: double-blind, randomized clinical trial of safety and effectiveness. J Bone Miner Res. 2011;26(10):2341-2357.

Hong S, Tian H et al. Neuroprotectin/protectin D1: endogenous biosynthesis and actions on diabetic macrophages in promoting wound healing and innervation impaired by diabetes. Am J Physiol Cell Physiol. 2014 Dec 1;307(11):C1058-67. doi: 10.1152/ajpcell.00270.2014.

Horrobin DF. Essential fatty acid metabolism and its modification in atopic eczema. Am J Clin Nutr 2000;71(1Suppl):367S372S.

Horrobin DF. Gamma-linolenic acid. Reviews in Contemporary Pharmacotherapy. 1990;Vol. 1 No. 1: 1-41.

Hyppönen E, Power C. Hypovitaminosis D in British adults at age 45y: nationwide cohort study of dietary and lifestyle predictors. Am J Clin Nutr 2007; 85:860-868.

Hyppönen E, Boucher BJ. Avoidance of vitamin D deficiency in pregnancy in the United Kingdom: the case for a unified approach in National policy. Br J Nutr 2010;104:309-314.

Ikai K, Imamura S. Role of eicosanoids in the pathogenesis of atopic dermatitis. Prostaglandins Leukot Essent Fatty Acids 1993;48(6):409-416.

Innis SM, Elias SL. Intakes of essential n-6 and n-3 polyunsaturated fatty acids among pregnant Canadian women. Am J Clin Nutr 2003:77:473-478.

Javanbakht M H, S A Keshavarz et al. Randomized controlled trial using vitamins E and D supplementation in atopic dermatitis. J Dermatolog Treat 2011;22(3):144-150.

Jenkinson A, Franklin MF et al. Dietary intakes of polyunsaturated fatty acids and indices of oxidative stress in human volunteers. Eur J Clin Med 1999;53(7):523-528.

Johnson EJ. The role of carotenoids in human health. Nutr Clin Care 2002;5:56-65.

Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr 2008;88(suppl):582S– 6S.

Jung JY, Kwon HH et al. Effect of dietary supplementation with omega-3 fatty acid and gamma-linolenic acid on acne vulgaris: a randomised, double-blind, controlled trial. Acta Derm Venereol 2014;94(5): 521-525.

Juturu V, Bowman JP, Deshpande J. Overall skin tone and skin-lightening-improving effects with oral supplementation of lutein and zeaxanthin isomers: a double-blind, placebo-controlled clinical trial. Clin Cosmet Investig Dermatol. 2016 Oct 7;9:325-332. eCollection 2016.

Kapoor R, Huang YS. Gamma linolenic acid: an antiinflammatory omega-6 fatty acid. Curr Pharm Biotechnol 2006;7(6):531534.

Katzman M. and Logan AC. Acne vulgaris: nutritional factors may be influencing psychological sequelae. Med Hypotheses 2007;69(5): 1080-1084.

Kawamura A, Ooyama K et al. Dietary supplementation of gamma-linolenic acid improves skin parameters in subjects with dry skin and mild atopic dermatitis. J Oleo Sci 2011;60(12): 597-607.

Khachik F, Beecher GR, Smith JC Jr. Lutein, lycopene, and their oxidative metabolites in chemoprevention of cancer. J Cell Biochem Suppl 1995;22:S236-S246.

Kim TH, Kim GD et al. Omega-3 fatty acid-derived mediator, Resolvin E1, ameliorates 2,4-dinitrofluorobenzene-induced atopic dermatitis in NC/Nga mice. Int Immunopharmacol. 2012 Dec;14(4):384-91. doi: 10.1016/j.intimp.2012.08.005.

Kiss B, Szántó M et al. Poly(ADP) ribose polymerase-1 ablation alters eicosanoid and docosanoid signaling and metabolism in a murine model of contact hypersensitivity. Mol Med Rep. 2015 Apr;11(4):2861-7. doi: 10.3892/mmr.2014.3044.

Kostic D, White WS, Olson JA. Intestinal absorption, serum clearance, and interactions between lutein and beta-carotene when administered to human adults in separate or combined oral doses. Am J Clin Nutr 1995;62:604-610.

Krishnan AV, Feldman D. Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Anny Rev Pharmacol Toxicol 2011;51:311-336.

Laitinen K, Hoppu U et al. Breast milk fatty acids may link innate and adaptive immune regulation: analysis of soluble CD14, prostaglandin E2, and fatty acids. Pediatr Res 2006;59:723-7.

Land, G. Oral administration of borago oil in atopic dermatitis. J Appl Cosmetology 1993;11(4):115–120.

Lassus A, Dahlgren AL et al. Effects of dietary supplementation with polyunsaturated ethyl ester lipids (Angiosan) in patients with psoriasis and psoriatic arthritis. J Int Med Res. 1990 Jan-Feb;18(1):68-73.

Latreille J, Kesse-Guyot E et al. Association between dietary intake of n-3 polyunsaturated fatty acids and severity of skin photoaging in a middle-aged Caucasian population. J Dermatol Sci. 2013 Dec;72(3):233-9. doi: 10.1016/j.jderm-sci.2013.07.006.

Le Marchand L, Hankin JH, Bach F, et al. An ecological study of diet and lung cancer in the South Pacific. Int J Cancer 1995;63:18-23.

Lee EH, Faulhaber D, Hanson KM, Ding W, Peters S, Kodali S, Granstein RD. Dietary lutein reduces ultraviolet radiation-induced inflammation and immuno-suppression. J Invest Dermatol. 2004:122:510-517.

Lee SH, Min DB. Effects, quenching mechanisms, and kinetics of carotenoids in chlorophyll-sensitized photooxidation of soybean oil. J Agric Food Chem 1990:38:1630-1634.

Lou YR, Peng QY et al. Effects of high-fat diets rich in either omega3 or omega-6 fatty acids on UVB-induced skin carcinogenesis in SKH-1 mice. Carcinogenesis 2011;32(7):1078-1084.

Lips P. Vitamin D status and nutrition in Europe and Asia. J Steroid Biochem 2007;103(3-5):620-625.

Landrum JT, Bone RA, Joa H, Kilburn MD, Moore LL, Sprague KE. A one year study of the macular pigment: the effect of 140 days of a lutein supplement. Exp Eye Res 1997;65:57–62.

Lee HR, Kim SW et al. The efficacy and safety of gamma-linolenic acid for the treatment of acne vulgaris. Int J Dermatol. 2014 Mar;53(3):e199-200. doi: 10.1111/ijd.12026.

Madden SMM, Garrioch CF, Holub BJ. Direct diet quantification indicates low intakes of (n-3) fatty acids in children 4 to 8 years old. J Nutri 2009:139:528-532.

Manku MS, Horrobin DF et al. Essential fatty acids in the plasma phospholipids of patients with atopic eczema. British Journal of Dermatology. 1984:110:643-648.

Marsen TA, Pollok M, Oette K, Baldamus CA. Pharmacokinetics of omega-3-fatty acids during ingestion of fish oil preparations. Prostaglandins Leukot Essent Fatty Acids. 1992 Jul;46(3):191-6.

Martens-Lobenhoffer J, Meyer FP. Pharmacokinetic data of gamma-linolenic acid in healthy volunteers after the administration of evening primrose oil (Epogam). Int J Clin Pharmacol Ther. 1998 Jul;36(7):363-6.

Mason RS, Reichrath J. Sunlight vitamin D and skin cancer. Anticancer Agents Med Chem. 2013 Jan; 13(1):83-97.

Maurice P D, Allen BR et al. Effects of dietary supplementation with eicosapentaenoic acid in patients with psoriasis. Adv Prostaglandin Thromboxane Leukot Res 1987a ;17B:647- 650.

Maurice P D, Allen BR et al. The effects of dietary supplementation with fish oil in patients with psoriasis. Br J Dermatol 1987b;117(5): 599-606.

Mayser P, Mrowietz U et al. Omega-3 fatty acid-based lipid infusion in patients with chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, multicenter trial. J Am Acad Dermatol 1998;38(4): 539-547.

McCusker MM, Grant-Kels JM.ealing fats of the skin: the structural and immunologic roles of the omega-6 and omega-3 fatty acids. Clin Dermatol. 2010 Jul-Aug;28(4):440-51. doi: 10.1016/j.clindermatol.2010.03.020.

Melni BC, Bahmer FA Die behandlung des atopischen ekzems mit glandol (tm) und epoleum(tm) deine vergleichende studie. [Treatment of atopic dermatitis with Glandol and Epoleum da comparative study] (German). Aktuelle Derm 1995;(21):215–219.

Miller AB, Gaudette LA. Cancers of skin, bone, connective tissue, brain, eye, thyroid and other specified and unspecified sites in Inuit. Acta Oncol 1996;35:607-16.

Miller C, Hale CP et al. Ultraviolet B injury increases prostaglandin synthesis through a tyrosine kinase-dependent pathway. Evidence for UVBinduced epidermal growth factor receptor activation. J Biol Chem 1994;269(5): 35293533.

Miller NJ, Sampson J, Candeias LP, Bramley PM, Rice-Evans CA. Anti-oxidant activities of carotenes and xanthophylls. FEBS Lett 1996:384:240-242.

Millikan LE. Rosacea as an inflammatory disorder: a unifying theory? Cutis 2004;73(1 Suppl): 58.

Morganti P, Fabrizi G, Bruno C. Protective effects of oral antioxidants on skin and eye function. Skinmed. 2004 Nov-Dec;3(6):310-6.

Morganti P, Bruno C, Guarneri F, Cardillo A, Del Ciotto P, Valenzano F. Role of topical and nutritional supplement to modify the oxidative stress. Int J Cosmet Sci. 2002 Dec;24(6):331-9.

Morse N L and Clough PM. A metaanalysis of randomized, placebocontrolled clinical trials of Efamol evening primrose oil in atopic eczema. Where do we go from here in light of more recent discoveries? Curr Pharm Biotechnol 2006;7(6): 503-524.

Morse NL, Reid AJ, St-Onge M. An open-label clinical trial assessing the efficacy and safety of Bend Skincare Anti-Aging Formula on minimal erythema dose in skin. Photodermatol Photoimmunol Photomed. 2017 Sep 8. doi: 10.1111/phpp.12350.

Morse PF, Horrobin DF et al. Meta-analysis of placebo-controlled studies of the efficacy of Epogam in the treatment of atopic ezema. Br J Dermatol. 1989;121:75-90.

Muggli, R. Systemic evening primrose oil improves the biophysical skin parameters of healthy adults. Int J Cosmet Sci 2005;27(4): 243-249.

Muggli R. Systemic evening primrose oil for irritated skin. Cosmetics and Toiletries Magazine. 2007;122(2):49-55.

Nakagawa K, Kiko T et al. Antioxidant effect of lutein towards phospholipid hydroperoxidation in human erythrocytes. Br J Nutr 2009;102(9):1280-1284.

Nicolaou A. Eicosanoids in skin inflammation. Prostaglandins Leukot Essent Fatty Acids. 2013 Jan;88(1):131-8.

Nikolakopoulou Z, Shaikh MH et al. The induction of apoptosis in pre-malignant keratinocytes by omega-3 polyunsaturated fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) is inhibited by albumin. Toxicol Lett. 2013 Apr 12;218(2):150-8. doi: 10.1016/j.toxlet.2013.01.021.

O'Neill ME, Thurnham DI. Intestinal absorption of beta-carotene, lycopene and lutein in men and women following a standard meal: response curves in the triacylglycerol-rich lipoprotein fraction. Br J Nutr 1998;79:149-159.

Orengo IF, Black HS, Wolf JE. Influence of fish oil supplementation on the minimal erythema dose in humans. Arch Dermatol 1992:284:219-221.

Palombo P, Fabrizi G, Ruocco V, Ruocco E, Fluhr J, Roberts R et al. Beneficial long-term effects of combined oral/topical anti-oxidant treatment with the carotenoids lutein and zeaxanthin on human skin: a double-blind, placebo-controlled study. Skin Pharmacol Physiol 2007:20:199-210.

Park HJ, Park JS, Hayek MG, Reinhart GA, Chew BP. Dietary fish oil and flaxseed oil suppress inflammation and immunity in cats. Vet Immunol Immunopathol. 2011 Jun 15;141(3-4):301-6. doi: 10.1016/j.vetimm.2011.02.024.

Peng YM, Peng YS, Lin Y, et al. Concentrations and plasma-tissue-diet relationships of carotenoids, retinoids, and tocopherols in humans. Nutr Cancer 1995;23:233-246.

Perez A, R Raab et al. Safety and efficacy of oral calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis. Br J Dermatol 1996;134(6):1070-1078.

Philips N, Keller T et al. Regulation of the extracellular matrix remodeling by lutein in dermal fibroblasts, melanoma cells, and ultraviolet radiation exposed fibroblasts. Arch Dermatol Res 2007;299(8):373-379.

Pilkington SM, Rhodes LE, Al-Aasswad NM, Massey KA, Nicolaou A. Impact of EPA ingestion on COX- and LOX-mediated eicosanoid synthesis in skin with and without a pro-inflammatory UVR challenge--report of a randomised controlled study in humans. Mol Nutr Food Res. 2014a:58:580-590.

Pilkington SM, Rhodes LE et al. Impact of EPA ingestion on COX- and LOX-mediated eicosanoid synthesis in skin with and without a pro-inflammatory UVR challenge--report of a randomised controlled study in humans. Mol Nutr Food Res. 2014b Mar;58(3):580-90. doi: 10.1002/mnfr.201300405.

Ribaya-Mercado JD, Garmyn M, Gilchrest BA, Russell RM. Skin lycopene is destroyed preferentially over beta-carotene during ultraviolet irradiation in humans. J Nutr 1995;125:1854-1859.

Rhodes LE, Durham BH, Fraser WD, Friedmann PS. Dietary fish oil reduces basal and ultraviolet Bgenerated PGE2 levels in skin and increases the threshold to provocation of polymorphic light eruption. J Invest Dermatol 1995:105: 532535.

Rhodes LE, O'Farrell S, Jackson MJ, Friedmann PS. Dietary fish-oil supplementation in humans reduces UVBerythemal sensitivity but increases epidermal lipid peroxidation. J Invest Dermatol 1994:103: 151154.

Rhodes LE, Shahbakhti H, Azurdia RM, Moison RM, Steenwinkel MJ, Homburg MI et al. Effect of eicosapentaenoic acid, an omega3 polyunsaturated fatty acid, on UVR-related cancer risk in humans. An assessment of early genotoxic markers. Carcinogenesis 2003:24: 919-925.

Rubin MG, Kim K et al. Acne vulgaris, mental health and omega-3 fatty acids: a report of cases. Lipids Health Dis 2008;7:36.

Ruzicka T, Simmet T et al. Skin levels of arachidonic acid-derived inflammatory mediators and histamine in atopic dermatitis and psoriasis. J Invest Dermatol 1986;86(2):105108.

Sabroe R A, Greaves MW. The pathogenesis of chronic idiopathic urticaria. Arch Dermatol 1997;133(8):1003-1008.

Saewan N, Jimtaisong A. Natural products as photoprotection. J Cosmet Dermatol. 2015:14:47-63.

Sawada Y, Honda T et al. Resolvin E1 inhibits dendritic cell migration in the skin and attenuates contact hypersensitivity responses. J Exp Med. 2015 Oct 19;212(11):1921-30. doi: 10.1084/jem.20150381.

Schaeffer L, Gohlke H et al. Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids. Hum Mol Genet 2006 Jun 1;15(11):1745-56.

Schwartz S, Frank E, Gierhart D, Simpson P, Frumento R. Zeaxanthin-based dietary supplement and topical serum improve hydration and reduce wrinkle count in female subjects. J Cosmet Dermatol. 2016 Dec;15(4):e13-e20.

Segger D, Matthies A et al. Supplementation with Eskimo Skin Care improves skin elasticity in women. A pilot study. J Dermatolog Treat 2008;19(5):279-283.

Serini S, Donato V et al. Docosahexaenoic acid reverts resistance to UV-induced apoptosis in human keratinocytes: involvement of COX-2 and HuR. J Nutr Biochem. 2011 Sep;22(9):874-85. doi: 10.1016/j.jnutbio.2010.08.004.

Serafini MR, Guimarães AG, Quintans JS, Araújo AA, Nunes PS, Quintans-Júnior LJ. Natural compounds for solar photoprotection: a patent review. Expert Opin Ther Pat. 2015;25:467-78.

Shao A, Hathcock JN Risk assessment for the carotenoids lutein and lycopene. Regulatory Toxicology and Pharmacology : RTP. 2006;45(3):289–98.

Sies H, Stahl W. Vitamins E and C, beta-carotene, and other carotenoids as antioxidants. Am J Clin Nutr 1995;62(6 Suppl):1315S-1321S.

Silverman DI, Ware JA, Sacks FM, Pasternak RC. Comparison of the absorption and effect on platelet function of a single dose of n-3 fatty acids given as fish or fish oil. Am J Clin Nutr. 1991 May;53(5):1165-70.

Simon D, Eng PA et al. Gamma-Linolenic Acid Levels Correlate with Clinical Efficacy of Evening Primrose Oil in Patients with Atopic Dermatitis. Adv Ther. 2014 Jan 17.

Simopoulos AP. Essential fatty acids in health and chronic disease. Am J Clin Nutr 1999;70(suppl):560S-9S.

Song EJ, Gordon-Thomson C, Cole L, Stern H, Halliday GM, Damian DL et al. 1$\alpha$,25-Dihydroxyvitamin D3 reduces several types of UV-induced DNA damage and contributes to photoprotection. J Steroid Biochem Mol Biol 2013;136:131-138.

Sorg O, Tran C, Carraux P, et al. Oxidative stressindependent depletion of epidermal vitamin A by UVA. J Invest Dermatol 2002;118:513-518.

Stahl W, Sies H. Bioactivity and protective effects of natural carotenoids. Biochim Biophys Acta. 2005:1740(2):101-107.

Stahl W, Sies H. Carotenoids and protection against solar UV radiation. Skin Pharmacol Appl Skin Physiol 2002;15:291-296.

Stewart JCM, Morse P et al. Treatment of severe and moderately severe atopic dermatitis with evening primrose oil (Epogam): a multi-centre study. Journal of Nutritional Medicine 1991;2:9-15.

Stone OJ. Psoriasis: highly reactive early cellular inflammation. Med Hypotheses 1990;31(1): 47-53.

Storey A, McArdle F et al. Eicosapentaenoic acid and docosahexaenoic acid reduce UVB- and TNFalpha induced IL8 secretion in keratinocytes and UVBinduced IL-8 in fibroblasts. J Invest Dermatol 2005;124(1): 248-255.

Surette M E, Koumenis IL et al. Inhibition of leukotriene synthesis, pharmacokinetics, and tolerability of a novel dietary fatty acid formulation in healthy adult subjects. Clin Ther 2003;25(3): 948-971.

Taylor M, Gonzalez M et al. Pathways to inflammation: acne pathophysiology. Eur J Dermatol 2011;21(3): 323-333.

Teichert A, Elalieh H, Elias PM, Welsh J, Bikle DD. Overexpression of hedgehog signaling is associated with epidermal tumor formation in vitamin D receptor-null mice. J Invest Dermatol. 2011 Nov;131(11):2289-97. doi: 10.1038/jid.2011.196. Epub 2011 Aug 4.

Terao J. Antioxidant activity of betacarotenerelated carotenoids in solution. Lipids 1989;24(7):659-661.

Thürmann PA, Schalch W, Aebischer JC, Tenter U, Cohn W. Plasma kinetics of lutein, zeaxanthin, and 3-dehydro-lutein after multiple oral doses of a lutein supplement. Am J Clin Nutr. 2005 Jul;82(1):88-97.

Tongkao-On W, Carter S, Reeve VE, Dixon KM, Gordon-Thomson C, Halliday GM et al. CYP11A1 in skin: an alternative route to photoprotection by vitamin D compounds. J Steroid Biochem Mol Biol 2015:148:72-78.

van den Elsen LW, Bol-Schoenmakers M et al. DHA-rich tuna oil effectively suppresses allergic symptoms in mice allergic to whey or peanut. J Nutr. 2014 Dec;144(12):1970-6. doi: 10.3945/jn.114.198515.

van der Pols JC, Xu C et al. Serum omega-3 and omega-6 fatty acids and cutaneous p53 expression in an Australian population. Cancer Epidemiol Biomarkers Prev. 2011 Mar;20(3):530-6. doi: 10.1158/1055-9965.EPI-10-0961.

van Het Hof KH, West CE, Weststrate JA, Hautvast JG. Dietary factors that affect the bioavailability of carotenoids. J Nutr 2000;130: 503-506.

Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr 1999;69(5): 842-856.

Vieth R, Bischoff-Ferrari H, Boucher BJ, Dawson-Hughes B, Garland CF, Heaney RP, Holick MF, Hollis BW, Lamberg-Allardt C, McGrath JJ et al. The urgent need to recommend an intake of vitamin D that is effective. Am J Clin Nutr 2007;85:649-650.

Wallingford SC, Hughes MC et al. Plasma omega-3 and omega-6 concentrations and risk of cutaneous basal and squamous cell carcinomas in Australian adults. Cancer Epidemiol Biomarkers Prev. 2013 Oct;22(10):1900-5. doi: 10.1158/1055-9965.EPI-13-0434.

Wang M, Tsao R et al. Antioxidant activity, mutagenicity/ anti-mutagenicity, and clastogenicity/anti-clastogenicity of lutein from marigold flowers. Food Chem Toxicol 2006; 44(9): 1522-1529.

Warthan MM, Sewell DS, Marlow RA, Warthan ML, Wagner RF. The economic impact of acute sunburn. Arch Dermatol 2003:139:1003-1006.

Weise C, Ernst D et al. Dietary polyunsaturated fatty acids and non-digestible oligosaccharides reduce dermatitis in mice. Pediatr Allergy Immunol. 2013 Jun;24(4):361-7. doi: 10.1111/pai.12073.

Weise C, Heunemann C et al. Dietary docosahexaenoic acid in combination with arachidonic acid ameliorates allergen-induced dermatitis in mice. Pediatr Allergy Immunol. 2011 Aug;22(5):497-504. doi: 10.1111/j.1399-3038.2010.01133.x.

Williams AW, Boileau TW, Erdman JW Jr. Factors influencing the uptake and absorption of carotenoids. Proc Soc Exp Biol Med 1998;218:106- 108.

Wingerath T, Sies H, Stahl W. Xanthophyll esters in human skin. Arch Biochem Biophys 1998;355:271- 274.

Xie L, Innis SM. Genetic variants of the FADS1 FADS2 gene cluster are associated with altered (n-6) and (n-3) essential fatty acids in plasma and erythrocyte phospholipids in women during pregnancy and in breast milk during lactation. J. Nutr. 2008:138:2222–2228.

Yeum KJ, Russell RM. Carotenoid bioavailability and bioconversion. Annu Rev Nutr 2002;22:483-504.

Yoshida S, Yasutomo K et al. Treatment with DHA/EPA ameliorates atopic dermatitis-like skin disease by blocking LTB4 production. J Med Invest. 2016;63(3-4):187-91. doi: 10.2152/jmi.63.187.

Zajdel A, Wilczok A et al. Polyunsaturated fatty acids inhibit melanoma cell growth in vitro. Acta Pol Pharm. 2013 Mar-Apr;70(2):365-9.

Ziboh V A, Cohen KA et al. Effects of dietary supplementation of fish oil on neutrophil and epidermal fatty acids. Modulation of clinical course of psoriatic subjects. Arch Dermatol 1986;122(11): 12771282.

Omega-3 Fatty Acids, fact sheet for health professionals. United States: National Institutes of Health, Office of Dietary Supplements. 2016 https://ods.od.nih.gov/factsheets/Omega3FattyAcids-HealthProfessional/#h4

Health Effects of UV Radiation. United States: Environmental Protection Agency, 2017. http: www.epa.gov/sunsafety/health-effects-uv-radiation

Canadian Partnership Against Cancer. The Economic Burden of Skin Cancer in Canada: Current and Projected. Canada: Canadian Cancer Society, 2010 Feb 26. http://www.cancer.ca/en/get-involved/take-action/what-we-are-doing/financial-hardship-of-cancer-in-canada-mb/?region=mb

Fish Oil Product Monograph. Available online: http://webprod.hc-sc.gc.ca/nhpid-bdipsn/monoReq.do?id=88&lang=eng (accessed on 7 February 2017).

Borage Oil Product Monograph. Available online: http://webprod.hc-sc.gc.ca/nhpid-bdipsn/monoReq.do?id=49&lang=eng (accessed on 7 February 2017).

Global Recommendations for EPA and DHA Intake. United States: Global Organization for EPA and DHA Omega-3. (accessed on November 8, 2017) file:///C:/Users/CBS/Downloads/Global%20Omega-3%20Intake%20Recommendations%20(5).pdf

Vitamin D Council (accessed on November 8, 2017) https://www.vitamindcouncil.org/about-vitamin-d/how-do-i-get-the-vitamin-d-my-body-needs/

NIH National Institutes of Health. Vitamin D https://ods.od.nih.gov/factsheets/VitaminD-Consumer/

Marigold Monograph, NNHPD Health Canada. Accessed online on Feb 5, 2018 at http://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq.do?atid=marei&lang=eng